CA2381165C - Novel quinuclidine derivatives and medicinal compositions containing the same - Google Patents

Novel quinuclidine derivatives and medicinal compositions containing the same Download PDF

Info

Publication number
CA2381165C
CA2381165C CA2381165A CA2381165A CA2381165C CA 2381165 C CA2381165 C CA 2381165C CA 2381165 A CA2381165 A CA 2381165A CA 2381165 A CA2381165 A CA 2381165A CA 2381165 C CA2381165 C CA 2381165C
Authority
CA
Canada
Prior art keywords
octane
hydroxy
bromide
azoniabicyclo
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2381165A
Other languages
French (fr)
Other versions
CA2381165F (en
CA2381165A1 (en
Inventor
Dolors Fernandez Forner
Maria Prat Quinones
Maria Antonia Buil Albero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Laboratorios Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8309225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2381165(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Almirall SA filed Critical Laboratorios Almirall SA
Publication of CA2381165F publication Critical patent/CA2381165F/en
Publication of CA2381165A1 publication Critical patent/CA2381165A1/en
Application granted granted Critical
Publication of CA2381165C publication Critical patent/CA2381165C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Abstract

A compound according to formula (I) wherein z© is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; which shows high affinity for muscarinic M3 receptors (Hm3).

Description

NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS
CONTAINING THE SAME

This invention relates to new therapeutically useful quinuclidine derivatives, to some processes for their preparation and to pharmaceutical compositions containing them.

The novel structures according to the invention are antimuscarinic agents with a potent and long lasting effect. In particular, these compounds show high affinity for muscarinic M3 receptors(Hm3).
In accordance with their nature as M: antagonists, the new compounds are suitable for treating the following diseases: respiratory disorders such as chronic obstructive pulmonary disease(COPD), chronic bronchitis, bronchial hyperreactivity, asthma and rhinitis; urological disorders such as urinary incontinence, pollakinuria in neuripenia pollakinuria, neurogenic or unstable bladder, cystospasm and chronic cystitis; and gastrointestinal disorders such as irritable bowel syndrome, spastic colitis, diverticulitis and peptic ulceration.
The compounds claimed are also useful for the treatment of the respiratory diseases detailed above in association with R, agonists, steroids, antiallergic drugs or phosphodiesterase IV inhibitors.

Compounds of the present invention may also be expected to have anti-tussive properties.

Depending on their nature the new compounds may be suitable for treating vagally induced sinus bradycardia.

Compounds with related structures have been described as anti-spasmodics and anti-cholinergic agents in several patents.

For example,in patent FR 2012964 are described quinuclidinol derivatives of the formula R

O

N
2 in which R is H, OH or an alkyl group having 1 to 4 carbon atoms; Rlis a phenyl or thienyl group; and R2 is a cyclohexyl, cyclopentyl or thienyl group, or, when R is H, Rland R2 together with the carbon atom to which they are attached, form a tricyclic group of the formula:

H
X /
\
in which X is -0-, -S- or -CH2-1 or an acid addition or quaternary ammonium salt thereof.
EP- 418716 describes thienyl carboxylate esters of formula Ra S

O

wherein A is a group (CH2)m~
Q
(CH2), --,-m and n= 1 or 2 0 Q is a -CH -CH2-, -CHZ-CH2-CH2-, -CH=CH-, group Q'is a =NR or NRR' group; R1 is a thienyl, phenyl, furyl, cyclopentyl or cyclohexyl group, optionally substituted; R2 is H, OH, C1-C9 alkoxy or C1-C9 alkyl and Ra is H, F, Cl, CH3- or -NR.
US 5,654,314 describes compounds of formula:
3 Ph 0 X
Ph R, +
O N_R, O
wherein R is an optionally halo- or hydroxy-substituted C1_9alkyl group; R is a C1_9 alkyl group; or R and R' together form a C9_6 alkylene group; X- is an anion; and Rl is H, OH, -CH2OH, C1_4 alkyl or C1_9 al koxy .
The present invention provides new quinuclidine derivatives with potent antagonist activity at muscarinic M3 receptors which have the chemical structure described in formula (I):

RI

C a(CH)p I
(CH2)" A - (CH2)m NR2 R3 X-(1) wherein:
- is a phenyl ring, a heteroaromatic group having from 4 to 9 ring members and one or more heteroatoms selected from nitrogen, oxygen and sulphur atoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group;
- R1, R2and R3 each independently represent a hydrogen atom, a halogen atom, a phenyl, a-OR9, -SR', -NR'R5, -NHCOR', -CONR9R5, -CN, -NOZ, -COOR' or -CF3 group, or a straight or branched C1 to Ce alkyl group which may optionally be substituted with a hydroxy group, wherein R 4 and R5 each independently represent a hydrogen atom, straight or branched C1 to C8 alkyl group or together form a C3 to Clo alicyclic ring; or Rl and R 2 together form a C6 to C14 aromatic ring, a C3 to Clo alicyclic ring or a heterocyclic ring having from 3 to 10 ring members and one or more heteroatoms selected from nitrogen, oxygen and sulphur atoms;
- n is an integer from 0 to 4;
4 - A represents a -CH=CR6-, -CR6=CH-, -CR6R'-, -CO-, -0-, -S-, -S(0) -, SO2 or -NR6- group, wherein R6 and R' each independently represent a hydrogen atom, straight or branched C1 to C8 alkyl group or R6 and R' together form a C3 to C10 alicyclic ring;
- m is an integer from 0 to 8; provided that when m = 0, A is not -CHz-;
- p is an integer from 1 to 2 and the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons;
- B represents a group of formula i) or ii):
I) II~ %JR 0 R9 R8 R10~ wherein R10 represents a hydrogen atom, a hydroxy or methyl group;

and Reand R9each independently represent S q 0 O ~ - ~ -wherein R" represents a hydrogen or halogen atom or a straight or branched C1 to C$ alkyl group and Q represents a single bond, -CH2-, -CHZ-CH2-, -0-, -0-CHz-, -S-, -S-CH2- or -CH=CH-; and - X represents a pharmaceutically acceptable anion of a mono or polyvalent acid.
In the quaternary ammonium compounds of the present invention represented by formula (I) an equivalent of an anion (X-)is associated with the positive charge of the N atom. X- may be an anion of various mineral acids such as, for example, chloride, bromide, iodide, sulfate, nitrate, phosphate, and organic acids such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and p-toluenesulfonate. X- is preferably an anion selected from chloride, bromide, iodide, sulphate, nitrate, acetate, maleate, oxalate or succinate. More preferably X- is chloride, bromide or trifluoroacetate.
The compounds of the present invention represented by the formula (I) described above, which may have one or more assymetric
5 carbons, include all the possible stereoisomers. The single isomers and mixtures of the isomers fall within the scope of the present invention.
If any of R' to R' or R" represents an alkyl group, it is preferred that said alkyl group contains 1 to 8, preferably 1 to 6 and more preferably 1 to 4 carbon atoms. In particular it is preferred that any alkyl group is represented by a methyl, ethyl, propyl, including i-propyl, butyl including a n-butyl, sec-butyl and tert-butyl.
The alicyclic and heterocyclic rings mentioned in relation to formula (I) comprise from 3 to 10, preferably from 5 to 7 members.
The aromatic rings mentioned in relation to formula (I) above contain from 6 to 14, preferably 6 or 10 members.
Preferred compounds of formula (I) are those wherein represents a phenyl, pyrrolyl, thienyl, furyl, biphenyl, naphthalenyl, 5, 6, 7, 8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, imidazolyl or benzothiazolyl group, in particular a phenyl, pyrrolyl, or thienyl group; R', R2 and R3 each independently represent a hydrogen or halogen atom, or a hydroxyl, methyl, tert-butyl, -CHZOH, 3-hydroxypropyl, -OMe, -NMe2 , -NHCOMe, -CONH21 -CN, -NOZ, -COOMe or -CF3 group, in particular a hydrogen atom, a hydroxy group or a halogen atom, wherein the halogen atom is preferably fluorine; n = 0 or 1; m is an integer from 1 to 6, particularly 1, 2 or 3;
A represents a -CHZ-, -CH=CH-, -CO-, -NH-, -NMe-, -0- or -S- group, in particular a-CHZ-, -CH=CH- or -0- group.
It is also preferred that p = 2 and the substituent group -OC(O)B
attached to the azoniabicyclo[2.2.2]octane is at the 3 position, preferably having the (R) configuration.
Further preferred compounds of formula I are those wherein B
is a group of formula i) or ii) as defined above wherein, if B is a group of formula (i), Reand R9 each independently represent a phenyl, 2-
6 thienyl, 3-thienyl, 2-furyl or 3-furyl group, wherein R" is hydrogen atom; and, if B is a group of formula (ii), Q represents a single bond, -CH2-, -CHZ-CHZ-, -0- or -S- group, in particular a single bond, -CH2-, -CH2-CH2- or -0- group, most preferably a single bond or -0- group ;

and in any case R10 is a hydrogen atom or a hydroxy or methyl group;
and when i) or ii) contain a chiral centre they may represent either the (R) or the (S) configuration.
Most preferably the -OC(O)B group in formula (I) is diphenylacetoxy, 2-hydroxy-2,2-diphenyl-acetoxy, 2,2-diphenylpropionyloxy, 2-hydroxy-2-phenyl-2-thien-2-yl-acetoxy, 2-furan-2-yl-2-hydroxy-2-phenylacetoxy, 2,2-dithien-2-ylacetoxy, 2-hydroxy-2,2-di-thien-2-ylacetoxy, 2-hydroxy-2,2-di-thien-3-ylacetoxy, 9 - h y d r o x y - 9 [ H]- f 1 u o r e n e- 9- c a r b o n y 1 o x y, 9-methyl-9[H]-fluorene-9-carbonyloxy, 9[H]-xanthene-9-carbonyloxy, 9 h y d r o x y - 9 [ H]- x a n t h e n e 9 c a r b o n y 1 o x y 9 - m e t h y 1 - 9 [ H ] - x a n t h e n e 9- c a r b o n y 1 o x y 2 , 2 - b i s ( 4 - f 1 u o r o p h e n y 1)- 2- h y d r o x y a c e t o x y, 2-hydroxy-2,2-di-p-tolylacetoxy, 2,2-difuran-2-yl-2-hydroxy acetoxy, 2,2-dithien-2-ylpropionyloxy, 9,10-dihydroanthracene-9-carbonyloxy, 9 [ H]- t h i o x a n t h e n e- 9- c a r b o n y 1 o x y, o r 5[H]-dibenzo[a,d]cycloheptene-5-carbonyloxy. Especially preferred compounds are those wherein the -OC(O)B group in formula (I) is diphenylacetoxy, 2-hydroxy-2,2-diphenyl-acetoxy, 2,2-diphenylpropionyloxy, 2-hydroxy-2-phenyl-2-thien-2-yl-acetoxy, 2-furan-2-yl-2-hydroxy-2-phenylacetoxy, 2,2-dithien-2-ylacetoxy, 2-hydroxy-2,2-di-thien-2-ylacetoxy, 2-hydroxy-2,2-di-thien-3-ylacetoxy, 9 - h y d r o x y - 9 [ H]- f 1 u o r e n e- 9- c a r b o n y 1 o x y, 9-methyl-9[H]-fluorene-9-carbonyloxy, 9[H]-xanthene-9-carbonyloxy, 9 - h y d r o x y - 9 [ H ] - x a n t h e n e - 9- c a r b o n y 1 o x y o r 9-methyl-9[H]-xanthene-9-carbonyloxy.
The most preferred compounds of formula (I) are those wherein the azoniabicyclo group is substituted on the nitrogen atom with a 3-phenoxypropyl, 2-phenoxyethyl, 3-phenylallyl, phenethyl, 4-phenylbutyl, 3-phenylpropyl, 3-[2-hydroxyphenoxy]propyl, 3-[4-fluorophenoxy]propyl, 2-benzyloxyethyl, 3-pyrrol-1-ylpropyl, 2-thien-2-ylethyl, 3-thien-2-
7 ylpropyl, 3-phenylaminopropyl, 3-(methylphenylamino)propyl, 3-phenylsulfanylpropyl, 3-o-tolyloxypropyl, 3 - ( 2 , 4 , 6 - t r i m e t h y 1 p h e n o x y ) p r o p y 1, 3-(2-tert-butyl-6-methylphenoxy)propyl, 3-(biphenyl-4-yloxy)propyl, 3- (5, 6, 7, 8-tetrahydronaphthalen-2-yloxy) -propyl, 3-(naphthalen-2-yloxy) propyl, 3-(naphthalen-1-yloxy)propyl, 3-(2-chlorophenoxy)propyl, 3-(2,4-difluorophenoxy)propyl, 3-(3-trifluoromethyl phenoxy)propyl, 3-(3-cyanophenoxy)propyl, 3-(4-cyanophenoxy)propyl, 3-(3-methoxyphenoxy)propyl, 3-(4-methoxyphenoxy)propyl, 3-(benzo[1,3]dioxol-5-yloxy)propyl, 3-(2-carbamoylphenoxy)propyl, 3-(3-dimethylaminophenoxy)propyl, 3-(4-nitrophenoxy)propyl, 3-(3-nitrophenoxy)propyl, 3-(4-acetylaminophenoxy)propyl, 3-(3-methoxycarbonylphenoxy)propyl, 3-[4-(3-hydroxypropyl) phenoxy]propyl, 3-(2-hydroxymethylphenoxy)propyl, 3-(3-hydroxymethylphenoxy) propyl, 3-(4-hydroxymethylphenoxy)propyl, 3-(2-hydroxyphenoxy)propyl, 3-(4-hydroxyphenoxy)propyl, 3-(3-hydroxyphenoxy)propyl, 4-oxo-4-thien-2- ylbutyl, 3-(l-methyl-[1H]-imidazol-2-ylsulfanyl)propyl, 3-(benzothiazol-2-yloxy)propyl, 3-benzyloxypropyl, 6-(4-phenylbutoxy)hexyl, 4-phenoxybutyl, or 2-benzyloxyethyl group. Especially preferred compounds are those wherein the azoniabicyclo group is substituted on the nitrogen atom with a 3-phenoxypropyl, 2-phenoxyethyl, 3-phenylallyl, phenethyl, 4-phenylbutyl, 3-phenylpropyl, 3-[2-hydroxyphenoxy]propyl, 3-[4-fluorophenoxy]propyl, 2-benzyloxyethyl, 3-pyrrol-l-ylpropyl, 2-thien-2-ylethyl or 3-thien-2-ylpropyl group.
The following compounds are intended to illustrate but not to limit the scope of the present invention.
3(R)-Diphenylacetoxy-l-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane;
bromide 3(R)-(2-Hydroxy-2,2-diphenyl-acetoxy)-l-(3-phenoxypropyl)-l-azoniabi cyclo[2.2.2]octane; bromide 3(R)-(2,2-Diphenylpropionyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.
2.2]octane; bromide 3 (R) - (2-Hydroxy-2-phenyl-2-thien-2-yl-acetoxy) -1- (3-phenoxypropyl) -1-azonia-bicyclo[2.2.2]octane; bromide
8 PCT/EP00/06469 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-1-(3-phenylallyl)-1-azo niabicyclo[2.2.2]octane; bromide 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-1-(2-phenoxyethyl)-1-azo niabicyclo[2.2.2]octane; bromide 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-l-(3-phenoxypropyl)-1-azo niabicyclo[2.2.2]octane; bromide 3(R)-(2,2-Dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-l-azoniabicyclo [2.2.2]octane; bromide 3(R)-(2-Hydroxy-2,2-di-thien-2-ylacetoxy)-l-phenethyl-l-azoniabicy clo[2.2.2]octane; bromide 3(R)-(2-Hydroxy-2,2-di-thien-2-ylacetoxy)-1-(4-phenylbutyl)-1-azonia bicyclo[2.2.2]octane; bromide 3 (R) - (2-Hydroxy-2, 2-dithien-2-ylacetoxy) -1- (3-phenoxypropyl) -1-azonia-bicyclo[2.2.2]octane; bromide 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylaceto xy)-l-azoniabicyclo[2.2.2]octane; chloride 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(2-hydroxyphenoxy)pro pyl]-l-azoniabicyclo[2.2.2]octane; trifluoroacetate 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-pyrrol-l-ylpropyl)-1-a zonia-bicyclo[2.2.2]octane; trifluoroacetate 3 (R) - (2-Hydroxy-2, 2-dithien-2-ylacetoxy) -1- (2-thien-2-ylethyl) -1-azo niabicyclo[2.2.2]octane; bromide 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-thien-2-ylpropyl)-1-a zoniabicyclo[2.2.2]octane; bromide 1- (2-Benzyloxyethyl) -3 (R) - (2-hydroxy-2, 2-dithien-2-ylacetoxy) -1-azon iabicyclo[2.2.2]octane; trifluoroacetate 3 (R) - (2-Hydroxy-2, 2-dithien-3-ylacetoxy) -1- (3-phenoxypropyl) -1-azoni abicyclo[2.2.2]octane; bromide 1-(3-phenylallyl)-3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-azo niabicyclo[2.2.2]octane; bromide 3 (R) - (9-Hydroxy-9 [H] -f luorene-9-carbonyloxy) -1- (3-phenoxypropyl) -1-a zoniabicyclo[2.2.2]octane; bromide 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-phenethyl-l-azoniabic yclo[2.2.2]octane; bromide 3(R)-(9-Hydroxy-9H-fluorene-9-carbonyloxy)-l-(3-thien-2-ylpropyl)-l-
9 azoniabicyclo[2.2.2]octane; bromide 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(3-phenylallyl)-1-azonia bicyclo[2.2.2]octane; bromide 3 (R) - (9-Methyl-9 [H] -fluorene-9-carbonyloxy) -1- (3-phenoxypropyl) -1-azo niabicyclo[2.2.2]octane; bromide 1-(4-Phenylbutyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo [2.2.2]octane; bromide 1-(2-Phenoxyethyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo [2.2.2]octane; bromide 1-(3-Phenoxypropyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo [2.2.2]octane; bromide 1-Phenethyl-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]
octane; bromide 3(R)-(9-Hydroxy-9[H]-xanthene-9-carbonyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide 3(R)-(9-Hydroxy-9[H]-xanthene-9-carbonyloxy)-1-phenethyl-l-azoniabicy clo[2.2.2]octane; bromide 3(R)-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-1-(3-thien-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane; bromide 3(R)-(9-Methyl-9[H]-xanthene-9-carbonyloxy)-1-(3-phenoxy-propyl)-1-a zonia-bicyclo[2.2.2]octane; bromide The present invention also provides processes for preparing compounds of formula (I).

The quaternary ammonium derivatives of general Formula I, may be prepared by reaction of an alkylating agent of general Formula II
with compounds of general Formula III. In Formulas I, II and III, R1, 2f R3, , A, X, B. n, m and p are as defined above.

B
R1 C (CHZ)n -A - (CHz)m -X +
N ` (CH2)P O~ O

II Methods a), b) III
O~B
R1 C (CH2)n - A - (CHZ)m N a(CHOP O R2 R3 X_ This alkylation reaction may be carried out by two different experimental procedures, a) and b)which are described below. In particular method b) provides a new experimental process, using solid phase extraction methodologies, that allows the parallel preparation 5 of several compounds. Methods a) and b) are described in the experimental section. Compounds of general Formula II which are not commercially available have been prepared by synthesis according to standard methods. For example, compounds wherein n = 0 and A= -0-,-S-or -NR6, wherein R6 is as defined above, were obtained by reaction of
10 the corresponding aromatic derivative or its potassium salt with an alkylating agent of general formula Y-(CH2)m-X, wherein X may be a halogen and Y may be a halogen or a sulphonate ester. In other examples, compounds of general Formula II, where n>=l were synthesised from the corresponding alcohol derivative of general Formula IV by known methods.

R1 a (CHz)õ - A - (CHz)m -OH

IV
Compounds of general Formula III may be prepared by three
11 different methods c,d and e illustrated in the following scheme and detailed in the experimental section.

OH
Method c N-(CHZ)P

By O V
O
VI

Method d OH 0~6 O N'(CHZ)P N~(CHz)P O
By - H QyCI V
O O
III
Method e OH
~NN`(CHZ)' BVN~ V

Some compounds of general formula III where B is a group of formula i) , Re and R9 are as described above and R10 is a hydroxy group, may also be prepared from the glyoxalate esters of general formula VII
by reaction with the corresponding organometallic derivative.

O
O R8 R9-[Mg,Li] OyB
N, (CHz) N' (CHZ)P O
P O
Method f VII III
Compounds of general formula VII may be prepared from the corresponding glyoxylic acids following the standard methods c, d and e described above and detailed in the experimental section. The glyoxalate derivatives of formula VII where R6 is a 2-thienyl or 2-furyl group have not been described before.
The following compounds are examples of compounds of general formula III and VII which have not been described before:
9-Methyl-9[H]-fluorene-9-carboxylic acid 1-azabicyclo[2.2.2]oct-3(R)
12 -yl ester (intermediate I-lc);
9-Methyl-9[H]-xanthene-9-carboxylic acid 1-azabicyclo[2.2.2]oct-3(R) -yl ester (intermediate I-ld);
2-Hydroxydithien-2-yl-acetic acid i-azabicyclo[2.2.2]oct-4-yl ester (intermediate I-4a).
Oxothien-2-yl-acetic acid 1-azabicyclo[2.2.2]oct-4-yl ester (intermediate I-4b).
Oxothien-2-yl-acetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester (intermediate I-4g).
Oxofuran-2-yl-acetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester (intermediate I-4e).
2-Hydroxy-2,2-difuran-2-yl-acetic acid 1-azabicyclo[2.2.2]oct-3(R) -yl ester (intermediate I-4d).
Compounds of Formula V could be:
4-hydroxy-l-azabicyclo[2.2.1]heptane, described in W0150080 4-hydroxy-l-azabicyclo[2.2.2]octane, described in Grob, C.A. et.al.
Helv.Chim.Acta (1958), 41, 1184-1190 3(R)-hydroxy-l-azabicyclo[2.2.2]octane or 3(S)-hydroxy-l-azabicyclo[2.2.2]octane, described in Ringdahl, R. Acta Pharm Suec.
(1979), 16, 281-283 and commercially available from CU Chemie Uetikon GmbH.
The following examples are intended to illustrate, but not to limit, the experimental procedures that have been described above.
The structures of the prepared compounds were confirmed by 'H-NMR and MS. The NMR were recorded using a Varian(RT"" 300 MHz instrument and chemical shifts are expressed as parts per million (b) from the internal reference tetramethyl silane. Their purity was determined by HPLC, using reverse phase chromatrography on a Waters(RT"" instrument, with values greater than 95% being obtained.
Molecular ions were obtained by electrospray ionization mass spectometry on a Hewlett(RTM) Packard instrument.

Method - a -Example 20- Preparation of 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenyl
13 acetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, bromide.
200 mg of ( Furan-2-yl) -hydroxy-phenylacetic acid 1-aza-bicyclo[2.2.2]
oct-3(R)-yl ester (0.6 mmol) were suspended in 4 ml of CH3CN and 6 ml of CHC13. To this suspension were added 0.48 ml (3 mmol) of 3-phenoxypropyl bromide. After stirring for 72 h at room temperature in inert atmosphere, solvents were evaporated. Ether was added and the mixture stirred . The solid obtained was filtered and washed several times with ether. The yield was 0.27 g(830) of title compound as a mixture of diastereomers.
'H- NMR (DMSO-d6): b 1.50-2.20 (m, 6H), 2.25 (m, 1H), 3.10 (m,1H), 3.20-3.60 (m, 6H), 3.95 (m, 1H), 4.05 (m, 2H), 5.20 (m, 1H), 6.25-6.35 (double dd, 1H), 6.45 (m, 1H), 6.95 (m, 4H), 7.30-7.50 (m, 7H), 7.70 (m, 1H) ; MS [M-Br]': 462; mp 166 C.

Method - b -Example 51 - Preparation of 3(R)-(2-Hydroxy-2,2-di-thien-2-yl acetoxy)-1-[3-(naphthalen- 1-yloxy)propyl]-1-azoniabicyclo[2.2.2]
octane; trifluoroacetate 60 mg (0.17 mmols) of hydroxy-dithien-2-yl-acetic acid 1-aza-bicyclo[2.2.2]oct-3(R)-yl ester were dissolved in lml of dmso.
To this solution 188 mg (0.85 mmol) of 3-(naphthalen-l-yloxy)- propyl chloride were added. After stirring overnight at room temperature, the mixture was purified by solid phase extraction with a cation exchange Mega Bond Elut cartridge, previously conditioned at pH = 7.5 with 0.1 M NaH2PO4 buffer. The reaction mixture was applied to the cartridge and washed first with 2 ml of DMSO and then three times with 5 ml of CH3CN, rinsing away all starting materials. The ammonium derivative was eluted with 5 ml of 0.03 M TFA solution in CH3CN:CHC13 (2:1). This solution was neutralized with 300 mg of poly(4-vinylpyridine), filtered and evaporated to dryness.
The yield was 17 mg (15%) of title compound. 'H- NMR (DMSO-d6) : b 1.7 - 2.1 (m, 4H), 2.2 - 2.4 (m, 3H), 3.2 - 3.6 (m, 7H), 4.0 (m, 1H), 4.2 (t, 2H), 5.25 (m, 1H), 7.0 (m 3H), 7.2 (m, 2H), 7.4 - 7.6 (m, 7H), 7.85 (d, 1H), 8.2 (d, 1H) ; MS [M-CF3COO]+: 534.
14 Method - c -Methyl ester derivatives of general Formula VI were prepared by standard methods of esterification from the corresponding carboxylic acid or following the procedures described in examples I-le, I-1f and I-lg or according to procedures described in literature: FR 2012964;
Larsson. L et al. Acta Pharm. Suec. (1974), 11(3), 304-308; Nyberg, K.
et.al. Acta Chem.Scand. (1970), 24, 1590-1596; and Cohen, V.I. et.al.
J.Pharm.Sciences (1992), 81, 326-329.
Example I-la- Preparation of (Furan-2-yl)hydroxyphenylacetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester.
3.24 g (0.014 mols) of (Furan-2-yl)-hydroxy-phenylacetic acid methyl ester were dissolved in 85 ml of toluene. To this solution were added 2.08 g (0.016 mols) of 3- (R) -hydroxy-l-azabicyclo [2.2.2] octane and 0.224 g (5.6 mmols) of HNa (60% dispersion in mineral oil). The mixture was refluxed with continuous removal of distillate and when necessary replacement with fresh toluene for 1.5 hours. The cooled mixture was extracted with 2N HC1 acid, the aqueous layer washed with ethyl acetate, basified with K2C03 and extracted with CHC13. The organic layer was dried over Na2SO4 and evaporated. The oil obtained (3.47 g) crystallised after cooling at room temperature. This solid was suspended in hexane and filtered. The yield was 2.5 g(540) of a mixture of diasteroisomers, mp: 140-142 C;GC/MS [M]+: 327;
'H- NMR (CDC13): b 1.20-1.70 (m, 4H), 1.90-2.10 (m, 1H), 2.45-2.80 (m, 5H), 3.10-3.30 (m, 1H), 4.8 (bs, OH), 4.90-5.0 (m, 1H), 6.20 (m, 1H), 6.35 (m, 1H), 7.30-7.50 (m, 4H), 7.60-7.70 (m, 2H).
After four crystallizations of 0.5 g of this mixture from boiling acetonitrile, 0.110 g of a pure diastereomer(1) were obtained.
From the mother liquors of crystallization was obtained the other diastereomer (2). (*:configuration not assigned). Diastereomer 1 was hydrolysed to yield (+)-2-hydroxy-2-phenyl-2-furan-2-ylacetic acid as a pure enantiomer, [a]ZSD = +5.6 (c=2, EtOH). Diastereomer 2 was hydrolysed to yield (-)-2-hydroxy-2-phenyl-2-furan-2-ylacetic acid as a pure enantiomer, [a]25p = -5.7 (c=2, EtOH).

Diastereomer 1: 2(*)-(Furan-2-yl)hydroxyphenylacetic acid 1-azabi cyclo [2.2.2] oct-3 (R) -yl ester.'H- NMR (CDC13): 5 1. 20-1 . 70 (m, 4H), 1.90 (m, 1H), 2.45-2.50 (m, 1H), 2.50-2.80 (m, 4H), 3.10-3.20 (m, 1H), 4.8 (bs, OH), 4.90-5.0 (m, 1H), 6.20 (m, 1H), 6.35 (m, 1H), 7.30-7.50 5 (m, 4H), 7.60-7.70 (m, 2H).
Diastereomer 2: 2(*)-(Furan-2-yl)hydroxyphenylacetic acid 1-azabi cyclo[2.2.2]oct-3(R)-yl ester. 'H- NMR (CDC13): 5 1.20-1.70 (m, 4H), 2.10 (m, 1H), 2.50-2.80 (m, 5H), 3.20-3.30 (m, 1H), 4.8 (bs, OH), 4.90-5.0 (m, 1H), 6.20 (m, 1H), 6.35 (m, 1H), 7.30-7.50 (m, 4H), 7.60-7.70 10 (m, 2H).

Example I-ib- Preparation of Furan-2-ylhydroxythien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester.
Prepared as in example I-1 a. The yield was 3.06 g (64.3 %) of a
15 mixture of diastereoisomers, mp: 172 C; GC/MS [M]+: 333;
'H- NMR (DMSO-d6): 5 1.21-1.27 (m, 1H), 1.41-1.60 (m, 3H), 1.87 (m, 1H), 2.36-2.69 (m, 5H), 3.02-3.14 (m, 1H), 4.75-4.82 (m, 1H), 6.24-6.25 (m, 1H), 6.42-6.45 (m, 1H), 7.01-7.06 (m, 1H), 7.11-7.14 (m, 2H), 7.51-7.54 (m, 1H), 7.66-7.69 (m, 1H).
Example I-lc- Preparation of 9-Methyl-9[H]-fluorene-9-carboxylic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester.
Prepared as in example I- 1 a. The yield was 3.34 g of an oil (80 0) This product was solidified by formation of the oxalate salt (1:1), mp:
186 C. MS [M free base + 1]+: 334.
Oxalate salt ,1H- NMR (DMSO-d6) : 5 1.43-1.55 (m, 2H), 1.68-1.78 (m, 2H), 1.75 (s, 3H) , 2.02 (m, 1H) , 2.70-2.90 (m, 1H) , 2.92-3.15 (m , 4H), 3.50-3.57 (m, 1H), 4.88 (m, 1H), 7.35-7.47 (m, 4H), 7.62-7.70 (m, 2H), 7.89-7.91 (m, 2H).
Example I-ld- Preparation of 9-Methyl-9[H]-xanthene-9-carboxylic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester.
Prepared as in example I- 1 a. The yield was 1.91 g of an oil (53%).
This product was solidified by formation of the oxalate salt (1:1), mp:
152 C. MS [M free base + 1]+: 350.
16 Oxalate salt ,1H- NMR (DMSO-d6) : 5 1.20-1.30 (m, 1H) , 1.40-1.52 (m, 1H), 1.64-1.81 (m, 2H), 1.90 (s, 3H), 2.0 (m, 1H), 2.53-2.66 (m, 1H), 2.71-2.76 (m, 1H) , 2.97-3.10 (m, 3H) , 3.44-3.52 (m, 1H) , 4.90-4.92 (m, 1H), 7.12-7.18 (m, 4H), 7.32-7.38 (m, 2H), 7.43-7.48 (m, 2H), 8.0-9.8 (bs, 1H, H+) .

Example I-le-Preparation of 9-Methyl-9[H]-fluorene-9-carboxylic acid methyl ester.
Lithium diisopropylamide (26.7 ml of a 2M solution in heptane/tetrahydrofurane/ethylbenzene, 0.053 mol) was added to a stirred solution of 9[H]-fluorene-9-carboxylic acid (5 g , 0.0237 mol) in THF (70 ml) at between 0 and 5 C in N2 atmosphere. The mixture was warmed to room temperature and refluxed 1. 5 hours. The reaction mixture was cooled to room temperature and a solution of CH3I (1.85 ml, 0.03 mol) in THF (1.85 ml) was added. The mixture was stirred overnight at room temperature and evaporated. To the residue in MeOH (70 ml) was added concentrated sulfuric acid (3.9 ml) in MeOH (25 ml), the mixture was refluxed for 2 hours and evaporated. The residue was partitioned between chloroform and saturated K2C03 solution. The aqueous layer was extracted again with chloroform and the organic layers were combined, washed with water, dried over sodium sulphate and evaporated to dryness to obtain 5.73 g of a brown oil. This product was purified by column chromatography (silica gel, hexane/ethyl acetate 95:5) to yield 4.43 g(78.50) of a pure product , structure confirmed by 'H-NMR.
'H- NMR (CDC13): 5 1.80 (s, 3H), 3.60 (s, 3H), 7.50-7.65 (m, 4H), 7.75 (m, 2H) , 8. 0 (m, 2H) .

Example I-lf -Preparation of 9-Methyl-9[H]-xanthene-9-carboxylic acid methyl ester.
Prepared as in example I-le. The yield was 2 . 65 g (47 . 2 0). 'H- NMR
(CDC13): 5 1.90 (s, 3H), 3.6 (s, 3H), 7.05-7.35 (m, 8H).

Example I-lg- Preparation of 9-Hydroxy-9[H]-xanthene-9-carboxylic acid methyl ester.
Lithium diisopropylamide (20.3 ml of a 2M solution in
17 heptane/tetrahydrofurane/ethylbenzene, 0.041 mol) was added to a stirred solution of 7 g ( 0.029 mol) of 9[H]-xantene-9-carboxylic acid methyl ester (prepared by a standard method) in THF (70 ml) at between 0 and 5 C in NZ atmosphere. The mixture was stirred 1 h at this temperature and then was added by N2 pressure to a dry solution of oxygen in ether at 0 C. After 30 min, an equal volum of NaHSO3 , 40%
aqueous solution, was added, and the reaction mixture was warmed to room temperature and stirred for 30 min. The two layers were separated and the aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, treated with NaHSO3 (40% aqueous solution), washed with water, dried over sodium sulphate and evaporated to dryness to obtain 8.89 g of a brown solid.
This procedure was repeated with 5 g of starting material yielding 6.04g of the same brown solid.
The products were combined and purified by column chromatography (silica gel, hexane/ethyl acetate 90:10) to yield 7.60g (global Rt:
59.4%) of a pure product , structure confirmed by 'H-NMR.
'H- NMR (DMSO-d6): 5 3.5 (s, 3H), 7.0 (s, 1H, OH), 7.2 (m, 4H), 7.4 (m, 2H), 7.55 (m, 2H).
Method - d -Example I-2a- Preparation of 10,11-Dihydro-5[H]-dibenzo[a,d]
cycloheptane-5-carboxylic acid 1-azabicyclo[2.2.2]oct-3-(R)-yl ester.
2.15g of 10, 11-Dihydro-5 [H] -dibenzo [a, d] cycloheptane-5-carboxylic acid (9.0 mmol) were dissolved in 40 ml of CHC13 (ethanol free) . The solution was cooled at 0 C and 0.86 ml of oxalyl chloride (9.9 mmols) and a drop of DMF were added. The mixture was stirred and allowed warm to room temperature. After an hour at this temperature the solvents were evaporated and the residue was dissolved in CHC13 and evaporated again. This procedure was repeated two times. The obtained oil was dissolved in 20 ml of toluene and added to a solution of 1.26 g (9.9 mmol) of 3- (R) -hydroxy-l-azabicyclo[2.2.2] octane in 40 ml of hot toluene. The reaction mixture was refluxed for 2 hours. After cooling the mixture was extracted with 2N HC1 acid. The aqueous layer was
18 PCT/EP00/06469 basified with K2C03 and extracted with CHC13. The organic layer was dried over Na2SO4 and evaporated to dryness. The residue was purified by column chromatography (silica gel, CHC13:MeOH:NH40H, 95:5:0.5) . The yield was 1.5 g (48 %); mp: 112-113 C; CG/MS [M]`: 347; 'H- NMR
(CDC13): 5 1.10-1.35 (m, 2H), 1.40-1.52 (m, 1H), 1.52-1.68 (m, 1H), 1.90 (m, 1H), 2.40-2.60 (m, 2H), 2.60-2.77 (m, 3H), 2.83-2.96 (m, 2H), 3.07-3.19 (m, 1H), 3.25-3.40 (m, 2H), 4.80 (m, 2H), 7.10-7.30 (m, 8H).
10,11-Dihydro-5[H]-dibenzo[a,d]cycloheptane-5-carboxylic acid was prepared as described in Kumazawa T. et al., J. Med. Chem., (1994), 37, 804-810.

Example I-2b- Preparation of 5[H]-Dibenzo[a,d]cycloheptene-5-carboxylic acid 1-azabicyclo[2.2.2]oct-3-(R)-yl ester.
Prepared as in example I-2a. The yield was 3.12 g(710); mp 129 C; MS
[M+1]+: 346; 'H- NMR (DMSO-d6): b 0.90-1.10 (m, 2H), 1.30-1.50 (m, 2H), 1.58 (m, 1H), 2.21-2.26 (m, 2H), 2.47-2.50 (m, 3H), 2.86-2.94 (m, 1H), 4.48-4.51 (m, 1H), 5.33 (s, 1H), 7.0 (m, 2H), 7.29-7.43 (m, 6H), 7.49-7.51 (m, 2H).
5[H]-Dibenzo[a,d]cycloheptene-5-carboxylic acid was prepared as described in M.A. Davis et al; J. Med. Chem., (1964), Vol 7, 88-94.
Example I-2c-Preparation of 9,10-Dihydroanthracene-9-carboxylic acid 1-azabicyclo[2.2.2]oct-3-(R)-yl ester Prepared as in example I-2a. The yield was 0.77 g(62.60); mp 139 C;
MS [M+1]+: 334; 'H- NMR (DMSO-d6): b 1.1-1.2 (m, 1H), 1.25-1.40 (m, 2H), 1.40-1.55 (m, 1H), 1.73 (m, 1H) , 2.20 (m, 1H), 2.35-2.65 (m, 4H), 2.90-2.98 (m, 1H) , 3.93-4.14 (dd, 2H, J = 1.8 Hz, J = 4.3 Hz), 4.56 (m, 1H) , 5.14 (s, 1H) , 7.25-7.35 (m, 4H) 7.35-7.50 (m, 4H).
9,10-Dihydro-anthracene-9-carboxylic acid was prepared as described in E. L. May and E. Mossettig; J. Am. Chem. Soc., (1948), Vol 70, 1077-9.
Method - e -Example 1-3. Preparation of 2,2-Diphenylpropionic acid 1-azabicyclo
19 [2.2.2]oct-3(R)-yl ester.

1.1 g (4.8 mmol) of 2,2-diphenylpropionic acid were dissolved in 20 ml of THF. To this solution were added 0.87 g (5.3 mmol) of 1,1'-carbonyldiimidazole and the mixture was refluxed for an hour. The reaction was monitored by TLC following the formation of the imidazolide. When the reaction was completed part of the solvent was evaporated and 0.67 g (5.3 mmol) of 3 -(R)-hydroxy-l-azabicyclo[2.2.2] octane were added. The reaction mixture was refluxed for 16 h, cooled, diluted with ether and washed with water. The organic layer was extracted with HC1 2N, the acid solution basified with K2C03 and extracted with CHC13. The organic solution was dried over Na2SO4 and evaporated to dryness to yield 1.21 g(75.20) of an oil that was identified as the title ester.

0.64 g (1.9 mmol) of 2,2-Diphenylpropionic acid 1-azabicyclo [2.2.2]oct-3(R)-yl ester were dissolved in 6 ml of ketone and 0.085 g( 0.95 mmol) of oxalic acid were added. After slow addition of ether a white solid was formed. The yield was 0.33g (45.6%) of oxalate of 2,2-Diphenyl-propionic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester; mp:
146 C; MS [M free base+1]+: 336.
Oxalate salt, 'H- NMR (CDC13): 6 1.40-1.64 (m, 2H), 1.90 (s, 3H), 1. 80-2. 0(m, 2H), 2.31 (m, 1H) , 2. 73-2 . 85 (m, 1H), 3. 0-3. 10 (m, 1H), 3.10-3.32 (m, 3H), 3.53-3.70 (m, 1H), 5.13 (m, 1H), 7.14-7.40 (m, lOH), 9.25 (broad band, 2H, H').

Method -f-Example I-4a- Preparation of 2-Hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-4-yl ester.
A solution of 2-thienylmagnesium bromide was prepared from 220 mg (9 mmols)of Magnesium and 0.86 ml (9 mmols) of 2-bromothiophene in 15 ml of THF. This solution was added to 1.95 g(7mmols) of oxothien-2-yl -acetic acid 1-azabicyclo[2.2.2]oct-4-yl ester (intermediate I-4b) dissolved in 20 ml of THF. The mixture was stirred at room temperature for 1 hour, refluxed for 1 hour, cooled, treated with a saturated solution of ammonium chloride and extracted with ether. After removal of the solvent the solid obtained was recrystallised from acetonitrile to yield 1.45 g,of a white solid (56o).1H- NMR (DMSO-d6) : b 1.80-2.0 (m, 6H), 2.80-3.0 (m, 6H), 7.0 (m, 2H), 7.13 (m, 2H) , 7.18 (s, 1H), 7.51 (m, 2H) ; MS [M+l]: 350; mp 174 C.

Example I-4b- Preparation of oxothien-2-yl-acetic acid 1-azabicyclo [2.2.2]oct-4-yl ester.
Oxalyl chloride (1.5ml, 0.017 mol) was added to a solution of oxothien-2-yl-acetic acid (2.24 g, 0,014 mol) and dimethylformamide (one drop) 10 in 30 ml of chloroform (etanol free) at 0 C. The mixture was stirred and allowed to warm at room temperature. After one hour the solvent was evaporated. The residue was dissolved in chloroform and evaporated again. This procedure was repeated two times. The product obtained was disolved in CHC13 (30 ml) and added to a suspension of 1.1g (0,009mols) 15 of 4-hydroxy-l-azabicyclo[2.2.2]octane, 1.8m1 of triethylamine (0,013mols), 0.6g (0.9mmols) of N-(methylpolystyrene)-4-(methylamino) pyridine at 70 C. The mixture was refluxed for 1 hour, cooled, filtered and washed with water. The title product was extracted with a solution of diluted HC1, washed with CHC13, basified with K2C03 and extracted
20 again with CHC13. After removal of the solvent 1.47g (45%) of a solid was obtained. 'H- NMR (dmso) : b 2.0 (m, 6H) , 2.9 (m, 6H) , 7.35 (m, 1H), 8.05 (m, 1H), 8.3 (m, 1H).

Example I-4c- Preparation of (Furan-2-yl)hydroxyphenylacetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester.

Phenylmagnesium bromide ,0.0057 mol (5.7 ml of a solution 1M in THF), was added to a solution of 1.3 g ( 0.0052 mol) of oxofuran-2-ylacetic acid l-azabicyclo[2.2.2]oct-3(R)-yl ester (intermediate I-4e-) dissolved in 15 ml of THF, at -70 C in N2 atmosphere. The mixture was stirred at this temperature for 10 minuts, and then warmed to room temperature . After 1 hour , the reaction mixture was treated with a saturated solution of ammonium chloride and extracted three times with ethyl acetate . The organic phases were combined, washed with water and dried over Na2SO4. After removal of the solvent, the solid obtained was treated with ether and filtered to yield 0.67 g (40 %) of
21 a product whose structure was confirmed by 'H-NMR. This compound was also prepared as is described in Example I-la (Method c) . The diastereomers were separated by crystallization from acetonitrile and distinguished by 'H-NMR.
Example I-4d- Preparation of 2-Hydroxy-2,2-difur-2-yl-acetic acid 1-azabicyclo [2.2.2]oct-3(R)-yl ester.

The title compound was synthesised as in example I-4c from intermediate I-4e- and 2-furanyl lithium which was prepared whith furane and butyl lithium following a standard method. The yield was 380 mg (8%) . 'H- NMR
(CDC13): b 1.2-1.4 (m, 1H), 1.4-1.8 (m, 3H), 2.0 (m, 1H), 2.6-2.85 (m, 5H), 3.2 (m, 1H), 5.0 (m, 1H), 6.4 (m, 3H), 7.3 (m, 1H), 7.5 (m, 2H) MS [M+1]': 318.

Example I-4e- Preparation of oxofuran-2-yl-acetic acid 1-azabicyclo [2.2.2]oct-3(R)-yl ester.

Oxalyl chloride (9.75 ml, 0.112 mol) was added to a solution of oxofuran-2-ylacetic acid (10 g, 0.071 mol) and dimethylformamide (one drop) in 150 ml of chloroform (etanol free) at 0 C. The mixture was stirred and allowed to warm at room temperature. After five hours the solvent was evaporated. The residue was dissolved in chloroform and evaporated again. This procedure was repeated two times. The product obtained was disolved in CHC13 (150 ml) and a solution of 3(R)-quinuclidinol (10.90 g, 0.086 mol) in CHC13 (150 ml) was added to this at 0 C. The mixture was stirred and allowed to warm at room temperature. After 15 h at r.t., the mixture was washed with 10%
aqueous potassium carbonate, then with water, dried over Na2SO4 and evaporated to give 9.34 g(52.50) of the title compound as a dark oil.
Estructure confirmed by NMR.
'H- NMR (CDC13) : b 1.40-1.60 (m, 1H) , 1.60-1.80 (m, 2H), 1.80-2.05 (m, 1H), 2.20 (m, 1H), 2.70-3.10 (m, 5H), 3.30-3.45 (m, 1H), 5.10 (m, 1H), 6.7 (m, 1H), 7.7 (m, 1H), 7.8 (m, 1H).

Example I-4f- Preparation of 2-Hydroxy-2-phenyl-2-thien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester.
22 The title compound was prepared as described in example I-4c from intermediate I-4g. The yield was 3 g(330) as a mixture of diastereomers. After five crystallizations of 1.5 g of this mixture from boiling isopropanol, 0.200 g of a pure diastereomer(1) were obtained. The mother liquors from first crystallization were enriched with the other diastereomer (2). Diastereomer 1 was hidrolysed to yield (+)-2-Hydroxy-2-phenyl-2-thien-2-ylacetic acid as a pure enantiomer ,[a]zSD = +25.4 (c=2, EtOH). This value was assigned to the R configuration provided that in literature (A.I.Meyers et.al.
J.Org.Chem. (1980),45(14), 2913) the 2(S) enantiomer has been described whith [a] 25D = - 20 (c=2, EtOH).
Diastereomer 1: 2 (R) -2-Hydroxy-2-phenyl-2-thien-2-ylacetic acid 1-aza bicyclo[2.2.2]oct-3(R)-yl ester. 'H-NMR (DMSO-d6): b 1.1-1.25 (m, 1H), 1.3-1.6 (m, 3H), 1.83 (m, 1H), 2.4-2.7 (m, 5H), 3.1 (m, 1H), 4.8 (m, 1H), 7.0 (m, 2H), 7.05 (m, 1H), 7.3-7.4 (m, 3H), 7.4-7.45 (m, 2H), 7.5 (m, 1H).
Diastereomer 2: 2 (S) -2-Hydroxy-2-phenyl-2-thien-2-ylacetic acid 1-aza bicyclo [2.2.2] oct-3 (R) -yl ester.1H-NMR (DMSO-d6) : b 1.1-1.25 (m, 1H), 1.4-1.6 (m, 3H), 1.9 (m, 1H), 2.3-2.7 (m, 5H), 3.05 (m, 1H), 4.8 (m, 1H), 7.0 (m, 2H), 7.05 (m, 1H), 7.3-7.4 (m, 3H), 7.4-7.45 (m, 2H), 7.5 (m, 1H).

Example I-4g- Preparation of oxothien-2-yl-acetic acid 1-azabicyclo [2.2.2]oct-3(R)-yl ester.
Oxalyl chloride (1.34 ml, 0.0154 mol) was added to a solution of oxothien-2-yl-acetic acid (2 g, 0,0128 mol) and dimethylformamide (one drop) in 30 ml of chloroform (etanol free) at 0 C. The mixture was stirred and allowed to warm at room temperature. After one hour the solvent was evaporated. The residue was dissolved in chloroform and evaporated again. This procedure was repeated two times. The product obtained was disolved in CHC13 (30 ml) and a solution of 3(R)-quinuclidinol (1.95g, 0.0154 mol) in CHC13 (30 ml) was added to this at 0 C. The mixture was stirred and allowed to warm at room temperature. After 1.5 h at r.t., the mixture was washed with 10%
aqueous potassium carbonate, then with water, dried over Na2SO4 and
23 evaporated to give 3.14 g(92.60) of the title compound as a yellow oil. 'H- NMR (CDC13) : b 1.40-1.50 (m, 1H) , 1.50-1.70 (m, 1H) , 1.70-1.80 (m, 1H), 1.90-2.0 (m, 1H), 2.15 (m, 1H), 2.70-3.05 (m, 5H), 3.30-3.40 (m, 1H), 5.05 (m, 1H), 7.20 (m, 1H), 7.85 (m, 1H), 8.10 (m, 1H) Other carboxylic acids of Formula B-C(O)OH, whose preparation (or the syntheses of their derivatives methyl ester, chloride or imidazolide) haven't been described in methods c,d,e or in the Examples I-le, I-lf and I-1g, and that are not commercially available, could be prepared as is described in the following references:

M.A. Davis et al; J. Med. Chem. (1963), 6, 513-516.
T. Kumazawa et al; J.Med. Chem, (1994), 37(6), 804-810.
M.A. Davis et al; J. Med. Chem., (1964), Vol(7), 88-94.
Sestanj, K; Can. J. Chem., (1971), 49, 664-665.
Burtner, R. ; J. Am. Chem. Soc., (1943), 65, 1582-1585 Heacock R.A. et al; Ann. Appl. Biol., (1958), 46(3), 352-365.
Rigaudy J. et.al; Bull. Soc. Chim. France, (1959), 638-43.
Ueda I. et al; Bull. Chem. Soc. Jpn; (1975), 48 (8), 2306-2309.
E.L. May et.al.; J. Am. Chem. Soc., (1948), 70, 1077-9.
Also included within the scope of the present invention are pharmaceutical composition which comprise, as the active ingredient, at least one quinuclidine derivative of general formula (I) in association with a pharmaceutically acceptable carrier or diluent.
Preferably the composition is made up in a form suitable for oral administration.

The pharmaceutically acceptable carrier or diluents which are mixed with the active compound or compounds, to form the composition of this invention are well-known per se and the actual excipients used depend inter alia on the intended method of administration of the composition.
Compositions of this invention are preferably adapted for oral administration. In this case, the composition for oral administration may take the form of tablets, film-coated tablets, liquid inhalant, powder inhalant and inhalation aerosol; all containing one or more
24 compounds of the invention; such preparations may be made by methods well-known in the art.
The diluents which may be used in the preparations of the compositions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents, if desired. Tablets or film-coated tablets may conveniently contain between 500 and 1 mg, preferably from 5 to 300 mg of active ingredient. The inhalant compositions may contain between 1 /ug and 1,000 /.,cg, preferably from 10 to 800 /-ig of active ingredient.In human therapy, the dose of the compound of general formula (I) depend on the desired effect and duration of treatment; adult doses are generally between 3 mg and 300 mg per day as tablets and 10,ug and 800 /.cg per day as inhalant composition.

PharmacolocTical Action The following examples demonstrate the excellent pharmacological activities of the compounds of the present invention. The results on human muscarinic receptors binding and in the test on bronchospasm in guinea pig, were obtained as described below.

Human muscarinic receptor studies.
The binding of [3H]-NMS to human muscarinic receptors was performed according to Waelbroek et al (1990) (1) . Assays were carried out at 25 C. Membrane preparations from stably transfected chinese hamster ovary-Kl cells (CHO) expressing the genes for the human muscarinic receptors Hm3 were used.
For determination of IC501 membrane preparations were suspended in DPBS to a final concentration of 89 pg/ml for the Hm3 subtype. The membrane suspension was incubated with the tritiated compound for 60 min. After incubation the membrane fraction was separated by filtration and the bound radioactivity determined. Non specific binding was determined by addition of 10-9 M atropine. At least six concentrations were assayed in duplicate to generate individual displacement curves.

COMPOUNDS BINDING TO RECEPTOR
No M, (ICso nM) ATROPINE 3.2 IPRATROPIUM 3.0 8 4.8 10 18 6.6 20 6.8 36 2.7 39 3.8 15 44 4.4 53 5.6 71 8.2 77 3.1 84 9.9 89 5.4 101 7.6 128 8.8 129 6.3 137 6.9 (1) M. Waelbroek, M. Tastenoy, J. Camus, J Christophe. Binding of selective antagonists to four muscarinic receptors (Ml to M4) in rat forebrain. Mol. Pharmacol. (1990) 38: 267-273.

Our results show that the compounds of the present invention have affinities for the M3 receptors which are very similar to the reference compounds.
The compounds of the invention preferably have high affinities for muscarinic M3 receptors (HM3), preferably human muscarinic receptors. Affinity levels can typically be measured by in vitro assays, for example, as described above.
Preferred compounds of the invention have an IC5- (nM) value for M3 receptors of less than 35, preferably less than 25,20 or 15, more preferably less than 10,8 or S.

Test on bronchospasm in guinea pig The studies were performed according to Konzett and Rossler (2) Aqueous solutions of the agents to be tested were nebulized and inhaled by anaesthetized ventilated male guinea pigs (Dunkin-Hartley) . The bronchial response to intravenous acetylcholine challenge was determined before and after drug administration and the percent change in pulmonary resistance at several time-points.
2. Konzett H., Rossler F. Versuchsanordnung zu Untersuchungen ander bronchialmuskulatur. Arch. Exp. Path. Pharmacol. 195: 71-74 (1940) The compounds of the present invention inhibited the bronchospasm response to acetylcholine with high potency and a long duration of action.
From the above described results one of ordinary skill in the art can readily understand that the compounds of the present invention have excellent antimuscarinic activity (M3) and thus are useful for the treatment of diseases in which the muscarinic M3 receptor is implicated, including respiratory diseases such as chronic obstructive pulmonary disease, chronic bronchitis, asthma and rhinitis, urinary diseases such as urinary incontinence and pollakinuria in neuripenia pollakinuria, neurogenic bladder, nocturnal enuresis, unstable bladder, cystospasm and chronic cystitis and gastrointestinal diseases such as irritable bowel syndrome, spastic colitis and diverticulitis.
The present invention further provides a compound of formula (I) or a pharmaceutically acceptable composition comprising a compound of formula(I) for use in a method of treatment of the human or animal body by therapy, in particular for the treatment of respiratory, urinary or gastrointestinal disease.
The present invention further provides the use of a compound of formula (I) or a pharmaceutically acceptable composition comprising a compound of formula (I) for the manufacture of a medicament for the treatment of respiratory, urinary or gastrointestinal disease.
Further, the compounds of formula (I) and pharmaceutical compositions comprising a compound of formula (I) can be used in a method of treating respiratory, urinary or gastrointestinal disease, which method comprises administering to a human or animai patient in need of such treatment an effective amount of a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I).

The present invention will be further illustrated by the following examples. The examples are given by way of illustration only and are not to be construed as limiting.

Example 1 3(R)-Diphenylacetoxy-l-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane;
bromide The title compound was synthesised according to methods d and a. The yield of final step was 500 mg , 81%. 'H- NMR (CDC13): b 1.72-2.18 (m, 6H), 2.35 (m, 1H), 3.0 (m, 1H), 3.23 (m, 1H), 3.59-3.88(m, 5H), 4.0 (m, 2H), 4.30 (m, 1H), 5.1 (s, 1H), 5.25 (m, 1H), 6. 8-6. 9(m, 2H), 6.9-7.0 (m, 1H), 7.2-7.4 (m, 12H) ; MS [M-Br]': 456; mp 129 C.
Example 2 3(R)-(2-Hydroxy-2,2-diphenylacetoxy)-1-(3-phenoxypropyl)-1-azoniabic yclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 280 mg ,420. 'H- NMR (DMSO-d6) : 6 1.5 - 1.7 (m, 2H), 1.9 - 2.1 (m, 4H), 2.3 (m, 1H), 3.1 (m, 1H), 3.2 - 3.5 (m, 6H), 3.9 - 4.1 (m, 3H), 5.25 (m, 1H), 6.8 (bs, OH), 6.95 (m, 3H), 7.2 - 7.5 (m, 12H); MS [M-Br]': 472; mp 199 C.

Example 3 3(R)-[2,2-Bis(4-fluorophenyl)-2-hydroxyacetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 400 mg , 85%. 'H- NMR (DMSO-d6) : b 1.5-1.65 (m, 1H), 1.7-1.8 (m, 1H), 1.85-2.0 (m, 2H), 2.05-2.2 (m, 2H), 2.3 (m, 1H), 3.1-3.2 (m, 1H), 3.3-3.5 (m ,6H), 3.95 (m, 1H), 4.05 (m, 2H), 5.25 (m, 1H), 6. 9-7. 0(m, 4H), 7. 1-7. 5(m, 10H) ; MS [M-Br] `: 508; mp 253 C.

Example 4 3(R)-[2,2-Bis(4-fluorophenyl)-2-hydroxyacetoxy]-1-phenethyl-l-azonia bicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 300 mg , 67 0. 'H- NMR (DMSO-d6) : 5 1. 5-1. 65 (m, 1H), 1.7-1.85 (m, 1H), 1.85-2.1 (m, 2H), 2.3 (m, 1H), 2.9-3.1 (m, 2H), 3.15-3.25 (m, 1H), 3.3-3.6 (m, 6H), 3.95-4.05 (m, 1H), 5.25 (m, 1H), 6.95 (s, OH), 7.1-7.5 (m, 13H); MS [M-Br]+: 478; mp 182 C.

Example 5 3(R)-(2-Hydroxy-2,2-di-p-tolylacetoxy)-1-(3-phenoxypropyl)-1-azonia bicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 500 mg ,540. 'H- NMR (DMSO-d6) : 5 1.55-1.8 (m, 2H), 1.85-2.0 (m, 2H), 2.05-1.15 (m, 2H), 2.3 (s, 7H), 3.05-3.15 (m, 1H), 3.25-3.5 (m, 6H), 3.95 (m, 1H), 4.05 (t, 2H), 5.2 (m, 1H), 6.8 (s, OH), 6.95 (m, 3H), 7.1-7.2 (m, 4H), 7.2-7.35 (m, 6H); MS [M-Br]+:500; mp 183 C.

Example 6 3(R)-(2-Hydroxy-2,2-di-p-tolylacetoxy)-1-phenethyl-l-azoniabicyclo[2 .2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 650 mg ,740. 1H- NMR (DMSO-d6) : 5 1.55-1.8 (m, 2H), 1.85-2.05 (m, 2H), 2.25 (s, 7H), 2.9-3.05 (m, 2H), 3.1-3.25 (m, 1H), 3.3-3.55 (m, 6H), 3.95 (m, 1H), 5.25 (m, 1H), 6.8 (s, OH), 7.1-7.2 (m, 4H), 7.2-7.35 (m, 9H); MS [M-Br]+:470; mp 144 C.

Example 7 3(R)-(2,2-Diphenylpropionyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods e and a. The yield of final step was 250 mg , 61o.1H- NMR (CDC13) : 5 1.47-1.60 (m, 1H), 1.8-2.0 (m, 1H), 2.0 (s, 3H), 2.0-2.15 (m, 4H), 2.39 (s, 1H), 2.6 (m, 1H), 2.92 (d, 1H), 3.6 (m, 1H), 3.7-3.9 (m, 4H), 4.0 (m, 2H) , 4.3 (m, 1H), 5.25 (m, 1H), 6.85 (m, 2H), 7.0 (m, 1H), 7.3 (m, 12H); MS [M-Br]+: 470; mp 186 C.

Example 8 3(R)-(2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised as a mixture of diastereomers according to methods c and a. The yield of final step was 520 mg , 62%.
1 H- NMR (DMSO-d6): b 1.5 - 1.95 (m, 4H), 2.1 (m, 2H), 2.3 (m, 1H), 5 3.1 (m, 1H), 3.3 - 3.5(m, 6H), 3.9 (m, 1H), 4.05 (t, 2H), 5.2 (m, 1H), 7.0 (m, 4H) , 7.15 (m, 2H) , 7.35 (m, 5H) , 7.5 (m, 3H) ; MS [M-Br]+: 478;
mp 220 C.

Example 9 10 3 (R) - [2 (R) - (2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy) ] -1- (3-phenoxypro pyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods f and b from intermediate I-4f,diastereomer 1. The yield of final step was 10 mg , 23%. 1 H- NMR (DMSO-d6) : b 1.5-1.6 (m, 1H), 1.65-1.75 (m, 1H), 1.8-2.0 15 (m, 2H), 2.05-2.1 (m, 2H), 2.3 (m, 1H), 3.05-3.2 (m, 1H), 3.25-3.55 (m, 6H), 3.85-3.95 (m, 1H), 4.0 (t, 2H), 5.2 (m, 1H), 6.95 (m,3H), 7.03 (m, 1H), 7.15 (dd, 1H), 7.2 (s, OH), 7.3-7.5 (m, 5H), 7.45-7.55 (m, 3H); MS [M-CF3COO]': 478.

Example 10 20 3(R)-[2(S)-(2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy)]-1-(3-phenoxypro pyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods f and b from intermediate I-4f,diastereomer 2. The yield of final step was 3 mg , 11%.1 H- NMR (DMSO-d6): b 1.6-1.75 (m, 2H), 1.8-2.0 (m, 4H), 2.25 (m,
25 1H), 2.8 (t, 2H), 2.95-3.1 (m, 1H), 3.15-3.5 (m, 6H), 3.8-3.95 (m, 1H), 5.2 (m, 1H), 6.92 (m,1H), 6.96-7.03 (m, 2H), 7.1 (dd, 1H), 7.18 (s, OH), 7.3-7.4 (m, 4H), 7.43-7.5 (m, 2H), 7.51 (dd, 1H); MS [M-CF3COO]`:
478.

30 Example 11 3(R)-[2(R)-(2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy)]-1-(3-phenylprop yl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods f and b from intermediate I-4f,diastereomer 1. The yield of final step was 9 mg , 22%. 1 H- NMR (DMSO-d6) : b 1.45-1.55 (m, 1H), 1.65-1.75 (m, 1H), 1.85-2.05 (m, 2H) , 2.3 (m, 1H) , 2.9-3.1(m, 2H) 3.1-3.25 (m, 1H) 3.25-3.55 (m, 6H), 3.9-4.0 (m, 1H), 5.25 (m, 1H), 7.05 (m, 1H), 7.15 (m, 1H), 7.2 (m, 1H), 7.25-7.4 (m, 8H), 7.45 (m, 2H, 7.55 (m, 1H); MS
[M-CF3C00]+: 448.
Example 12 3 (R) - [2 (R) - (2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy) ] -1- (3-phenylprop yl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods f and b from intermediate I-4f,diastereomer 1. The yield of final step was 11 mg , 260.1 H- NMR (DMSO-d6): 5 1.45-1.55 (m, 1H), 1.6-1.75 (m, 1H), 1.8-2.0 (m, 4H) , 2.25 (m, 1H) , 2. 55 (t, 2H) , 3. 0-3. 1 (m, 1H) , 3. 15-3. 55 (m, 6H), 3.8-3.9 (m, 1H), 5.2 (m, 1H), 7.0 (m, 1H), 7.1 (m, 1H), 7.15-7.4 (m, 9H), 7.45 (m, 2H), 7.5 (m, 1H); MS [M-CF3C0O]+: 462.
Example 13 3(R)-[2(R)-(2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy)]-1-(2-thien-2-yl ethyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods f and b from intermediate I-4f,diastereomer 1. The yield of final step was 10 mg , 24%. 1 H- NMR (DMSO-d6) : 6 1.45-1.55 (m, 1H), 1.65-1.75 (m, 1H), 1.8-2.0 (m, 2H), 2.3 (m, 1H), 3.1-3.6 (m, 9H), 3.9-4.0 (m, 1H), 5.25 (m, 1H), 7.0 (m, 3H), 7.15 (dd, 1H), 7.2 (s, OH), 7.3-7.4 (m, 3H), 7.45-7.55 (m, 4H); MS [M-CF3C0O]+:454.

Example 14 3(R)-[2(R)-(2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy)]-1-(3-thien-2-yl propyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods f and b from intermediate I-4f,diastereomer 1. The yield of final step was 8 mg , 19%. 1 H- NMR (DMSO-d6) : b 1.45-1.6 (m, 1H), 1.65-1.75 (m, 1H), 1.8-2.05 (m, 4H), 2.25 (m, 1H), 2.8 (t, 2H), 3.0-3.15 (m, 1H), 3.2-3.5 (m, 6H), 3.8-3.95 (m, 1H), 5.2 (m, 1H), 6.92 (m,1H), 6.96-7.03 (m,2H), 7.13 (dd, 1H), 7.2 (s, OH), 7.3-7.4 (m, 4H), 7.45-7.5 (m, 2H), 7.52 (dd, 1H); MS [M-CF3C00]+: 468.

Example 15 3(R)-[2(S)-(2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy)]-1-(3-thien-2-yl propyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods f and b from intermediate I-4f,diastereomer 2. The yield of final step was 7 mg , 260.1 H- NMR (DMSO-d6) : 6 1.6-1.75 (m, 2H), 1.8-2.0 (m, 4H), 2.25 (m, 1H), 2.8 (t, 2H), 2.95-3.1 (m, 1H), 3.15-3.5 (m, 6H), 3.8-3.95 (m, 1H), 5.2 (m, 1H), 6.92 (m,1H), 6.96-7.03 (m, 2H), 7.1 (dd, 1H), 7.18 (s, OH), 7.3-7.4 (m, 4H), 7.43-7.5 (m, 2H), 7.51 (dd, 1H); MS [M-CF3COO]+:
468.

Example 16 3(R)-[2(R)-(2-Hydroxy-2-phenyl-2-thien-2-ylacetoxy)]-1-(2-phenoxyeth yl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods f and b from intermediate I-4f,diastereomer 1. The yield of final step was 11 mg , 26a.1 H- NMR (DMSO-d6): b 1.5-1.6 (m, 1H), 1.65-1.75 (m, 1H), 1.8-2.0 (m, 2H), 2.25 (m, 1H), 3.15-3.6 (m, 5H), 3.7 (m, 2H), 4.0 (m, 2H), 4.4 (m, 2H), 5.25 (m, 1H), 6.95-7.03 (m,4H), 7.12 (dd, 1H), 7.2 (s, OH), 7.3-7.4 (m, 5H), 7.4-7.5 (m, 3H); MS [M-CF3COO]+: 464.

Example 17 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-1-(3-phenylallyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised as a mixture of diastereomers according to methods c and a. The yield of final step was 240 mg , 77%.
'H-NMR (DMSO-d6) : 6 1.55-2.0 (m, 4H) , 2.27 (m, 1H), 3.05-3.55 (m, 5H), 3.88-3.98 (m, 1H), 4.0-4.10 (m, 2H), 5.21 (m,1H), 6.23-6.31 (doble dd, 1H), 6.36-6.48 (m, 2H), 6.83-6.90 (dd, 1H), 6.95 (d, OH), 7.26-7.66 (m, 11H); MS [M-Br]+: 444; mp 99 C.

Example 18 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-1-(2-phenoxyethyl)-1-a zoniabicyclo[2.2.2] octane; bromide The title compound was synthesised as a mixture of diastereomers according to methods c and a. The yield of final step was 210 mg , 66%.
'H- NMR (DMSO-d6) 5 1.50-2.05 (m, 4H) 2.27 ( m, 1H) , 3.20 (m, 1H) 3.37-3.65 (m, 4H) 3.65-3.75 (m, 2H) 4.04 (m, 1H) , 4.40 (m, 2H) 5.21 (m, 1H), 6.23-6.32 (doble dd, 1H), 6.44 (m, 1H), 6.94-7.04 (m, 4H) , 7.33-7.50 (m, 7H) , 7.64 (m, 1H); MS [M-Br]+: 448; mp 163 C.
Example 19 3(R)-[2(*)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)]-1-(2-phenoxyeth yl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b from intermediate I-la, diastereomer 1. The yield of final step was 11 mg, 230.1 H- NMR (DMSO-d6) : 5 1.65-1.80 (m, 2H) , 1.80-2.10 (m, 2H) , 2.27 (m, 1H), 3.15-3.65 (m, 5H), 3.68 (m, 2H), 4.0 (m, 1H), 4.40 (t, 2H), 5.20 (m, 1H), 6.23 (d, 1H), 6.42 (m, 1H), 6.92-7.04 (m, 4H), 7.30-7.38 (m, 5H), 7.44-7.50 (m, 2H), 7.64 (m, 1H); MS [M-CF3CO0]a: 448.

Example 20 3 (R) - (2-Furan-2-yl-2-hydroxy-2-phenylacetoxy) -1- (3-phenoxypropyl) -1-azoniabicyclo[2.2.2] octane; bromide The title compound has been described in method -a-.
Example 21 3(R)-[2(*)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)]-1-(3-phenoxy pro pyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a from intermediate I-la, diastereomer 1. The yield of final step was 1.15 g 99%. 1 H- NMR (DMSO-d6) : 5 1.60-2.20 (m, 6H) , 2.25 (m, 1H) , 3.10 (m,1H), 3.20-3.60 (m, 6H), 3.95 (m, 1H), 4.05 (m, 2H), 5.20 (m, 1H), 6.25 (dd, 1H), 6.45 (m, 1H), 6.95 (m, 4H), 7.30-7.50 (m, 7H), 7.70 (m, 1H) ; MS [M-Br]': 462; mpl56 C.

Example 22 3 (R) - [2 (*) - (2-Furan-2-yl-2-hydroxy-2-phenylacetoxy) ] -1- (3-phenoxy pro pyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b from intermediate I-la, diastereomer 2. The yield of final step was 10 mg, 20%. 1 H- NMR (DMSO-d6) : b 1.50-2.20 (m, 6H) , 2.25 (m, 1H), 3.10 (m,1H), 3.20-3.60 (m, 6H) , 3.95 (m, 1H), 4.05 (m, 2H) , 5.20 (m, 1H), 6.35 (dd, 1H), 6.45 (m, 1H), 6.95 (m, 4H), 7.30-7.50 (m, 7H), 7.70 (m, 1H); MS [M-CF3COO]+: 462.

Example 23 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-1-phenethyl-l-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised as a mixture of diastereomers according to methods c and b. The yield of final step was 12 mg, 13%.
'H- NMR (DMSO-d6): b 1.5 (m, 1H), 1.7 (m, 1H), 1.9 - 2.05 (m, 2H), 2.3 (m, 1H), 2.95 (m, 2H), 3.15 (m, 1H), 3.25 - 3.55 (m, 6H), 3.95 (m, 1H), 5.25 (m, 1H), 6.3 (d, 1H), 6.45 (m, 1H), 6.95 (d, 1H), 7.25 - 7.45 (m, 8H), 7.5 (m, 2H), 7.7 (m, 1H) MS [M-CF3COO]+: 432.
Example 24 3(R)-[2(*)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)]-1-phenethyl-l-azo niabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b from intermediate I-la, diastereomer 1. The yield of final step was 16 mg, 400.1 H- NMR (DMSO-d6) : b 1.65-1.80 (m, 2H), 1.90-2.05 (m, 2H), 2.3 (m, 1H), 2.95 (m, 2H), 3.15 (m, 1H), 3.25 - 3.55 (m, 6H), 3.95 (m, 1H), 5.25 (m, 1H), 6.26 (dd, 1H), 6.46 (m, 1H), 6.95 (s, 1H, OH), 7.25 - 7.45 (m, 8H), 7.5 (m, 2H), 7.7 (m, 1H) ; MS [M-CF3CO0]+:
432.

Example 25 3(R)-[2(*)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)]-1-phenethyl-l-azo niabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b from intermediate I-la, diastereomer 2. The yield of final step was 14 mg, 35%. 1 H- NMR (DMSO-d6) : 5 1.50-1.80 (m, 2H) , 1. 90-2. 05 (m, 2H), 2.3 (m, 1H), 2.95 (m, 2H), 3.15 (m, 1H), 3.25 - 3.55 (m, 6H), 3.95 (m, 1H), 5.25 (m, 1H), 6.32 (dd, 1H), 6.46 (m, 1H), 6.95 (s, 1H, OH), 7.25 - 7.45 (m, 8H), 7.5 (m, 2H), 7.7 (m, 1H) ; MS [M-CF3COO]+:
432.

5 Example 26 3(R)-[2(*)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)]-1-(3-phenylprop yl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b from intermediate I-la, diastereomer 1. The yield of final step was 10 mg, 10 210.1 H- NMR (DMSO-d6): 5 1.60-1.75 (m, 2H), 1.80-2.0 (m, 4H), 2.25 (m, 1H), 2.50-2.60 (m, 2H), 3.0 (m, 1H), 3.10-3.50 (m, 6H), 3.83 (m, 1H), 5.17 (m, 1H), 6.25 (d, 1H), 6.45 (m, 1H), 6.95 (s, 1H), 7.20-7.40 (m, 8H), 7.46-7.48 (m, 2H), 7.66 (m, 1H); MS [M-CF3COO]+: 446.

15 Example 27 3(R)-[2(*)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)]-1-(2-thien-2-yl ethyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b from intermediate I-la, diastereomer 1. The yield of final step was 9 mg, 20 19%.1 H- NMR (DMSO-d6): 5 1.65-1.80 (m, 2H), 1.85-2.05 (m, 2H), 2.30 (m, 1H), 3.10-3.40 (m, 3H), 3.40-3.60 (m, 6H), 3.95 (m, 1H), 5.24 (m, 1H), 6.27 (d, 1H), 6.47 (m, 1H), 6.96 (s, 1H), 7.0-7.04 (m 2H) , 7.36-7.
48 (m, 4H), 7.49-7.54 (m, 2H), 7.70 (m, 1H).; MS [M-CF3COO]+: 438.
25 Example 28 3(R)-[2(*)-(2-Etiaran-2-yl-2-hydroxy-2-phenylacetoxy)]-1-(3-thien-2-yl propyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b from intermediate I-la, diastereomer 1. The yield of final step was 9 mg, 30 19%.1 H- NMR (DMSO-d6): 5 1.60-1.75 (m, 2H), 1.80-2.05 (m, 4H), 2.26 (m, 1H), 2.81 (t, 2H), 3.02 (m, 1H), 3.10-3.45 (m, 6H), 3.85 (m, 1H), 5.18 (m, 1H), 6.25 (d, 1H), 6.45 (m, 1H), 6.90-7.0 (m, 3H), 7.32-7.42 (m, 4H), 7.45-7.51 (m, 2H), 7.66 (m, 1H); MS [M-CF3COO]+: 452.

35 Example 29 3(R)-(2-Furan-2-yl-2-hydroxy-2-thien-2-ylacetoxy)-1-phenethyl-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised as a mixture of diastereomers according to methods c and b. The yield of final step was 18 mg, 20%.
'H- NMR (DMSO-d6): 5 1.65 - 2.05 (m, 4H), 2.3 (m, 1H), 3.0 (m, 2H), 3.15 - 3.6 (m, 7H), 3.95 (m, 1H), 5.25 (m, 1H), 6.35 (dd, 1H), 6.45 (m, 1H), 7.05 (m, 1H), 7.2 (dd, 1H), 7.25 - 7.5 (m, 6H), 7.55 (m, 1H), 7.65 (m, 1H) ; MS [M-CF3COO] +: 438.

Example 30 3(R)-(2-Furan-2-yl-2-hydroxy-2-thien-2-ylacetoxy)-1-(2-phenoxyethyl) -1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised as a mixture of diastereomers according to methods c and b. The yield of final step was 22 mg, 23%.
1H- NMR (DMSO-d6): 5 2.65 - 2.05 (m, 4H), 2.3 (m, 1H), 3.15 - 3.65 (m, 7H), 4.05 (m, 1H), 4.4 (m, 2H), 5.15 (m, 1H), 6.35 (dd, 1H), 6.45 (m, 1H), 6.95 - 7.05 (m, 4H), 7.15 (d, 1H), 7.3 - 7.4 (m, 3H), 7.5 (dd, 1H), 7.65 (d, 1H); MS [M-CF3COO]+: 454.

Example 31 3(R)-(2-Furan-2-yl-2-hydroxy-2-thien-2-ylacetoxy)-1-(4-oxo-4-phenylbutyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised as a mixture of diastereomers according to methods c and b. The yield of final step was 15.4 mg, 15%.
'H- NMR (DMSO-d6): 5 1.65 - 2.1 (m, 6H), 7.05 - 7.55 (m, 9H), 3.95 (m, 1H), 5.1 (m, 1H), 6.35 (dd, 1H), 6.5 (m, 1H), 7.05 (m, 1H), 7.15 (m, 1H), 7.3 (d, 1H), 7.55 (m, 3H), 7.7 (dd, 2H), 8.0 (d, 2H);
MS [M-CF3COO]': 480.

Example 32 1-(3-phenoxypropyl)-3(R)-(2-Furan-2-yl-2-hydroxy-2-thien-2-yl-acetoxy)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised as a mixture of diastereomers according to methods c and a. The yield of final step was 100 mg, 41%.
1H- NMR (DMSO-d6) : 6 1.65 - 2.05 (m, 4H) , 2.1 - 2.0 (m, 2H), 2.3 (m, 1H), 3.15 (m, 1H), 3.25 - 3.6 (6H), 3.9 - 4.1 (m, 3H), 5.1 (m, 1H), 6.35 (d, 1H), 6.45 (s, 1H), 6.95 (m, 3H), 7.05 (m, 1H), 7.2 (d, 1H), 7. 3(m, 3H), 7.55 (d, 1H), 7.7 (s, 1H) ; MS [M-Br] 520; mp 173 C.
Example 33 1-(3-phenoxypropyl)-3(R)-(2,2-difuran-2-yl-2-hydroxy acetoxy)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods f and a. The yield of final step was 200 mg, 60%. 'H- NMR (DMSO-d6) : 6 1.6-2.20 (m, 6H), 2.3 (m, 1H), 2.95-3.65 (m, 7H), 3.80-4.10 (m, 3H), 5.2 (m, 1H), 6.3-6. 6 ( m , 4H), 6.8-7.0 (m, 3H), 7 . 1 ( s , OH), 7. 3(m, 2H), 7.7 (m, 2H); MS [M-Br]+: 452.

Example 34 3(R)-(2,2-Dithien-2-ylacetoxy)-1-(2-phenoxyethyl)-1-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 240 mg , 60%.1H- NMR ( DMSO-d6): 6 1.85-2.10 (m, 4H), 2.30 (s, 1H), 3.40 (m, 1H), 3.44-3.80 (m, 6H), 4.10 (m, 1H), 4.45 (m, 2H), 5.20 (m, 1H), 5.90 (s, 1H), 6.95-7.05 (m, 5H), 7.05-7.15 (m, 2H), 7.30-7.40 (m, 2H), 7.45 (m, 2H); MS [M-Br]+: 454; mp 98 C.
Example 35 3(R)-(2,2-Dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 280 mg , 83o.1H- NMR (DMSO-d6) : b 1.80-2.06 (m, 4H), 2.06-2.20 (m, 2H), 2.20-2.30 (m, 1H), 3.20-3.65 (m,7H), 3.90-4.10 (m, 3H), 5.20 (m, 1H), 5.90 (s, 1H), 6.95-7.05 (m, 5H), 7.05-7.20 (m,2H), 7.30-7.35 (m, 2H), 7.50 (m, 2H); MS [M-Br]+: 468; mp 148 C.

Example 36 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-phenethyl-l-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 180 mg , 59o.1H- NMR (DMSO-d6): 5 1.65 - 2.0 (4H, m), 2.35 (m, 1H), 3.0 (m, 2H), 3.2 - 3.6 (m, 7H), 3.95 (m, 1H), 5.25 (m, 1H), 7.0 (m, 2H), 7.2 (m, 2H), 7.35 (m, 5H), 7.55 (m, 3H);
MS [M-Br]+: 454; mp 216 C.

Example 37 3 (R) - (2-Hydroxy-2,2-dithien-2-ylacetoxy) -1- (3-phenylpropyl) -1-azonia bicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 450 mg , 58o.1H- NMR (CDC13) : 5 1.8 - 2.1 (m, 6H), 2.4 (m, 1H), 2.6 (m, 2H), 3.4 - 3.8 (m, 7H), 4.2 (m, 1H), 5.25 (m, 1H), 6.1 (bs, OH), 6.9 (m, 2H), 7.1 - 7.3 (m, 9H); MS [M-Br]+:
468; mp 64 C.

Example 38 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenylallyl)-1-azonia bicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 260 mg , 34%. 'H- NMR (CDC13) : 5 1.8 - 2.05 (m, 4H), 2.4 (m, 1H), 3.55 - 3.95 (m, 5H), 4.15 - 4.5 (m, 3H), 5.25 (m, 1H), 5.9 (s, OH), 6.15 (m, 1H), 6.85 (t, 1H), 6.9 - 7.05 (m, 3H), 7.15 (m, 1H), 7.2 - 7.45 (m, 7 H); MS [M-Br]+: 466; mp 124 C.

Example 39 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(4-phenylbutyl)-1-azonia bicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 320 mg , 40%. 'H- NMR (CDC13) : 5 1. 6- 2.0 (m, 8H), 2.4 (m, 1H), 2.6 (m, 2H), 3.4 - 3.8 (m, 7H), 4.2 (m, 1H), 5.25 (m, 1H), 6.05 (bs, OH), 6.95 (m, 2H), 7 . 1 - 7. 3(m, 9H) ; MS [M-Br]':
482; mp 64 C.

Example 40 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(4-oxo-4-phenylbutyl)-1-a zoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 16 mg , 15o.1H- NMR (DMSO-d6) : 5 1.7 - 2.0 (m, 6H), 2.15 (m, 1H), 3.1 (t, 2H), 3.15 - 3.55 (m, 7H), 3.95(m, 1H), 5.25 (m, 1H), 7.0 (d, 2H), 7.15 (d, 2H), 7.55 (m, 5H), 7.65 (t, 1H), 8.0 (d, 2H) ; MS [M-CF3COO] +: 496.

Example 41 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenylaminopropyl)-1-a zoniabicyclo[2.2.2] octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 14 mg , 14%. 'H- NMR ( DMSO-d6) : 6 1.7 - 2.0 (m, 5H), 2.3 (m, 1H), 3.0 - 3.5 (m, 9H), 3.9 (m, 1H), 5.25 (m, 1H), 5.65 (t, 1H), 6.55 (m, 3H), 7.0 (d, 2H), 7.1 (t, 2H), 7.15 (m, 2H), 7.5 (m, 3H) ; MS [M-CF3COO] +: 483.

Example 42 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(methylphenylamino)pro pyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 20 mg , 19o.1H- NMR (DMSO-d6) : b 1.65 - 2.0 (m, 6H), 2.9 (s, 3H), 3.1 (m, 1H), 3.2 - 3.45 (m, 8H), 3.95 (m, 1H), 5.2 (m, 1H), 6.65 ( t , 1H), 6.75 (d, 2H), 7. 0(m, 2H), 7, 2(m, 4H), 7.5 (m, 3H); MS [M-CF3COO]+: 497.

Example 43 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenylsulfanylpropyl)-1-azoniabicyclo[2.2.2] octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 800 mg , 83o.1H- NMR (DMSO-d6) : b 1.6 -1.9 (m, 6H), 2.3 (m, 1H), 2.95 (t, 2H), 3.05 (m, 1H), 3.2 - 3.5 (m, 6H), 3.9 (m, 1H), 5.2 (m, 1H), 7.0 (m, 2H), 7.15 (m, 2H), 7.2 (m, 1H), 7.35 (m, 4H), 7.5 (m, 2H); MS [M-Br] +: 500.

Example 44 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane; bromide The title compound was synthesised according to methods c and a. The 5 yield of final step was 490 mg, 90o.1H- NMR (DMSO-d6) : 5 1.7 (m, 2H), 1.95 (m, 2H), 2.1 (m, 2H), 2.3 (m, 1H), 3.2 (m, 1H), 3.45 (m, 6H), 4.0 (m, 3H), 5.15 (m, 1H), 6.9 (m, 3H), 7.0 (m, 2H), 7.2 (m,2H), 7.3 (t, 2H), 7.5 (m, 3H); MS [M-Br]+: 484; mp 227 C.

10 Example 45 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-o-tolyloxypropyl)-1-azoniabicyclo[2.2.2] octane; trifluoroacetate The title compound was synthesised according to methods c and b The yield of final step was 19 mg , 18%.1H-NMR (DMSO-d6) : 5 1.7- 2.0 (m, 15 4H), 2.1 - 2.2 (m, 5H), 2.3 (m, 1H), 3.15 - 3.5 (m, 7H), 3.9 - 4.05 (m, 3H), 5.05 (m, 1H), 6.85 ( t , 1H), 6 . 9 ( d , 1H), 7. 0(m, 2H), 7.15 (m, 4H), 7.5 (m, 3H); MS [M-CF3CO0]+: 498.

Example 46 20 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(2,4,6-trimethylphenox y)propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 22 mg , 20o.1H- NMR ( DMSO-d6): 5 1.7(m, 2H), 1.95 (m, 2H), 2.1 (m, 2H), 2.2 (s, 9H), 2.35 (m,1H), 3.2 - 3.5 (m, 25 7H), 3.7 (t,2H), 3.95 (m, 1H), 5.25 (m, 1H), 6.8 (s, 2H), 7.0 (m, 2H), 7.2 (m, 2H), 7.5 (m, 3H); MS [M-CF3COO]+: 526.

Example 47 1-[3-(2-tert-Butyl-6-methylphenoxy)propyl]-3(R)-(2-hydroxy-2,2-30 dithien-2-ylacetoxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 18 mg , 16o.1H- NMR (DMSO-d6): 5 1.3 (s, 9H), 2.7 (m, 2H), 2.9 (m, 2H), 2.1 (m, 2H), 2.2 (s, 3H), 2.3 (m, 1H), 3.2 - 3.5 (m, 7H), 3.8 (t, 2H), 3.95 (m, 1H), 5.2 (m, 1H), 6.9 - 7.15 (m, 35 7H), 7.5 (m, 3H); MS [M-CF3COO]': 554.

Example 48 1-[3-(Biphenyl-4-yloxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo[2.2.2]-octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 22 mg , 19o.1H- NMR (DMSO-d6): 5 1.7 (m, 2H), 1.9 (m, 2H), 2.15 (m, 2H), 2.3(m, 1H), 3.2 - 3.5(m, 7H), 3.95(m, 1H), 4.1 (t, 2H), 5.25 (m, 1H), 7.0 (m, 4H), 7.2(m, 2H), 7.3(t, 1H), 7.45 (t, 2H), 7.5 (m, 3H), 7.6 (m, 4H); MS [M-CF3COO]+: 560.

Example 49 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)-propyl]-1-azoniabicyclo[2.2.2]octane;
trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 23 mg , 21o.1H- NMR (DMSO-d6): 5 1.7 (m, 6H), 1.9 - 2.1 (m, 4H), 2.3 (m, 1H), 2.65 (m, 4H), 3.15 - 3.5 (m, 7H), 3.95 (m, 2H), 5.25 (m, 1H), 6.65 (m, 2H), 6.95 (d, 1H), 7.0 (m, 2H), 7.2 (m, 2H), 7.5 (m, 3H); MS [M-CF3COO] ': 538.

Example 50 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(naphthalen-2-yloxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 17 mg , 15%. 'H- NMR (DMSO-d6) : 5 1.7 - 2.0 (m, 4H), 2.1 (m, 1H), 2.35 (m, 1H), 3.15 - 3.35 (m, 7H), 3.95 (m, 1H), 4.17 (t, 2H), 5.25 (m, 1H), 7.0 (m, 2H), 7.15 (m, 3H), 7.35 (m, 2H), 7.5 (m, 4H), 7.85 (m, 3H); MS [M-CF3COO]+: 534.

Example 51 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(naphthalen-l-yloxy)propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound has been described in method -b-.
Example 52 1-[3-(2-Chlorophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetox y)-1-azoniabicyclo [2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 20 mg , 18%. 'H- NMR (DMSO-d6) : 5 1.65 - 2.0 (m, 6H), 2.35 (m, 1H), 3.2 (m, 1H), 3.3 - 3.55 (m, 6H), 3.95 (m, 1H), 4.15 (t, 2H) , 5.25 (m, 2H) , 7. 0 (m, 3H) , 7.2 (m, 3H) , 7. 35 (t, 1H) , 7.45 (d, 1H), 7.55 (m, 3H); MS [M-CF3C0O]+: 519.

Example 53 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo [2.2.2]octane; chloride The title compound was synthesised according to methods c and a. The yield of final step was 180 mg , 59o.1H- NMR (DMSO-d6): b 1.65 - 2.15 (m, 6H), 2.25 (m, 1H), 3.2 (m, 1H), 3.25 - 3.55 (m, 6H), 3.95 (m, 2H), 4.0 (t, 2H), 5.25 (m, 1H), 7.0 (m, 4H), 7.15 (m, 4H), 7.55 (m, 3H); MS
[M-Cl]+: 502; mp 160 C.

Example 54 1-[3-(2,4-Difluorophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 14 mg , 13%. 'H- NMR (DMSO-d6) 5 1.65 - 2.0 (m, 4H), 2.15 (m, 2H), 2.35 (m õ 1H), 3.2 (m, 1H), 3.25 - 3.35 (m, 6H), 3.95 (m, 1H), 4. 1(t, 2H), 5.15 (m, 1H), 7.05 (m, 3H), 7.2 (d, 2H), 7.25 - 7.35 (m, 2H), 7.55 (m, 3H); MS [M-CF3CO0]+: 520.

Example 55 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-trifluoromethyl phenoxy)propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg , 17%. 'H- NMR (DMSO-d6) : b 1.65 - 2.1 (m, 6H), 2.35 (m, 1H), 3.2 (m, 1H), 3.3 - 3.55 (m, 6H), 3.95 (m, 1H), 4.15 (t, 2H), 5.25 (m, 1H), 7.0 (m, 2H), 7.2 (m, 2H), 7.25 -7.35 (m, 3H), 7.5 - 7.6 (m, 4H); MS [M-CF3COO]+: 552.

Example 56 1-[3-(3-Cyanophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo [2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 18 mg , 170. 'H- NMR (DMSO-d6) : b 1.65 - 2.1 (m, 6H), 2.35 (m, 1H), 3.2 (m, 1H), 3.3 -3.55 (m, 6H), 3.95 (m, 1H), 4.15 (t, 2H), 5.25 (m, 1H), 7.0 (m, 2H), 7, 18 (m, 2H) , 7.3 (d, 1H), 7.45 (m, 2H), 7.55 (m, 4H); MS [M-CF3COO]+: 509.

Example 57 1-[3-(4-Cyanophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 180 mg , 53%. 'H- NMR (DMSO-d6) : b 1.65 - 2.2 (m, 6H), 2.3 (m, 1H), 3.2 (m, 1H), 3.3 - 3.55 (m, 6H), 3.95 (m, 1H), 4.15 (t, 2H), 5.25 (m, 1H), 7.0 (m, 2H), 7.1 (d, 2H), 7.15 (m, 2H), 7.5 (m, 2H), 7.8 (d, 2H); MS [M-Br]+: 509; mp 158 C.

Example 58 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-methoxyphenoxy) propyl]-1-azonia bicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg , 18%. 'H- NMR (DMSO-d6) : b 1.65 - 2.15 (m, 6H), 2.15 (m, 1H), 3.2 (m, 1H), 3.3 - 3.5 (m, 6H), 3.75 (s, 3H), 3.95 (m, 1H), 4.0 (t, 2H), 5.25 (m, 1H), 6.55 (m, 3H), 7.0 (m, 2H), 7.2 (m, 3H), 7.55 (m, 3H) ; MS [M-CF3COO]+: 514.

Example 59 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(4-methoxyphenoxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 14 mg , 13%. 'H- NMR (DMSO-d6) : b 1.65 - 2.15 (m, 6H), 2.35 (m, 1H), 3.2 (m, 1H), 3.3 - 3.55 (m, 6H), 3.7 (s, 3H), 3.9 -4.0 (m, 3H), 5.25 (m, 1H), 6.9 (s, 4H), 7.0 (m, 2H), 7.15 (m, 2H), 7.5 (m, 3H) ; MS [M-CF3COO]': 514.

Example 60 1-[3-(Benzo[1,3]dioxol-5-yloxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2 -ylacetoxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg , 17%. 'H- NMR (DMSO-d6): 6 1.65 - 2.15 (m, 7H), 2.3 (m, 1H), 3.15 (m, 1H), 3.25 - 3.5 (m, 6H), 3.9 - 4.0 (m, 3H), 5.25 (m, 1H), 5.95 (s, 2H), 6.4 (d, 1H), 6.65 (s, 1H), 6.85 (d, 1H), 7.0 (m, 2H), 7.2 (m, 2H), 7.5 (m, 3H); MS [M-CF3COO]+: 528.

Example 61 1-[3-(2-Carbamoylphenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 18 mg , 16o.1H- NMR (DMSO-d6) : b 1.65 - 2.0 (m, 4H), 2.2 (m, 2H), 2.3 (m, 1H), 3.15 (m, 1H), 3.25 - 3.55 (m, 6H), 3.95 (m, 1H) , 4.15 (t, 2H) , 5.25 (m, 1H) , 7.0 - 7.2 (m, 6H) , 7.4 - 7.6 (m, 6H) , 7. 7 (d, 1H) ; MS [M-CF3COO] +: 527.

Example 62 1-[3-(3-Dimethylaminophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-y lacetoxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg , 17%. 'H- NMR (DMSO-d6) : b 1.65 - 2.15 (m, 6H), 2.3 (m, 1H), 2.85 (s, 6H), 3.1 - 3.5 (m, 7H), 3.85 - 4.0 (m, 3H), 5.25 (m, 1H), 6. 2(m, 1H), 6.25 (d, 1H), 6.35 (d, 1H), 7.0 (m, 2H), 7.1 (t, 1H), 7.2 (m, 2H), 7.5 (m, 3H); MS [M-CF3COO] ': 527.
Example 63 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(4-nitrophenoxy)propyl ]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 22 mg , 20%. 'H- NMR (DMSO-d6): b 1.65 - 2.0 (m, 4H), 2.2 (m, 2H), 2.3 (m, 1H), 3.2 (m, 1H), 3.3 - 3.5 (m, 6H), 3.95 (m, 1H), 4.2 (t, 2H), 5.25 (m, 1H), 7.0 (m, 2H), 7.15 (m, 4H), 7.5 (m, 3H), 8.15 (d, 2H); MS [M-CF3COO]+: 529.

Example 64 3 (R) - (2-Hydroxy-2,2-dithien-2-ylacetoxy) -1- [3- (3-nitrophenoxy) propyl]-1-azoniabicyclo [2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The 5 yield of final step was 18 mg , 16%. 'H- NMR (DMSO-d6): 6 1.65 - 2.2 (m, 6H), 2.3 (m, 1H), 3.15 - 3.55 (m, 7H), 3.95 (m, 1H), 4.2 (t, 2H), 5.25 (m, 1H), 7.0 (m, 2H), 7.2 (m, 2H), 7.45 (dd, 1H), 7.55 (m, 3H), 7.6 (t, 1H), 7.75 (s, 1H), 7.85 (d, 1H); MS [M-CF3COO]+: 529.

10 Example 65 1-[3-(4-Acetylaminophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg , 17%. 'H- NMR (DMSO-d6) 6 1.65 - 2.15 15 (m, 6H), 2.0 (s, 3H), 2.3 (m, 1H), 3.2 (m, 1H), 3.3 - 3.55 (m, 6H), 3.9 - 4.0 (m, 3H), 5.25 (m, 1H), 6.85 (d, 2H), 7.0 (m, 2H), 7.2 (m, 2H), 7.5 (m, 5H), 9.8 (s, 1H); MS [M-CFjCOO]+: 541.

Example 66 20 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-methoxycarbonylphen oxy)propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 18 mg , 16%. 'H- NMR (DMSO-d6) : 5 1.65 - 2.2 (m, 6H), 2.3 (m, 1H), 3.2 (m, 1H), 3.3 - 3.5 (m, 6H), 3.85 (s, 3H), 25 3.95 (m, 1H), 4.1 (t, 2H), 5.25 (m, 1H), 7.0 (m, 2H), 7.15 (m, 2H), 7.25 (dd, 1H), 7.45 - 7.6 (m, 6H); MS [M-CF3COO]+: 542.

Example 67 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-{3-[4-(3-hydroxypropyl) 30 phenoxy]propyl}-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 14 mg , 13%. 'H- NMR (DMSO-d6) : b 1.6 - 2.15 (m, 8H), 2.3 (m, 1H), 2.55 (t, 2H), 3.2 (m, 1H), 3.25 - 3.55 (m, 9H), 3.85 - 4.0 (m, 3H), 4.45 (t, OH), 5.25 (m, 1H), 7.85 (d, 2H), 7.0 35 (m, 2H), 7.1 (d, 2H), 7.15 (m, 2H), 7.5 (m, 2H); MS [M-CF3COO]+: 542.

Example 68 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(2-hydroxymethylphenoxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 16 mg , 15%. 'H- NMR (DMSO-d6) : 5 1.7 - 2.2 (m, 6H), 2.35 (m, 1H), 3.1 - 3.5 (m, 7H), 3.9 - 4.05 (m, 3H), 4.5 (m, 2H), 5.0 (t, OH), 5.15 (m, 1H), 6.9 - 7.05 (m, 4H), 7.2 (m, 2H), 7.4 (d, 1H), 7.5 (m, 3H); MS [M-CF3COO] 514.

Example 69 3 (R) - (2-Hydroxy-2,2-dithien-2-ylacetoxy) -1- [3- (3-hydroxymethylphenoxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 16 mg , 15%. 'H- NMR (DMSO-d6) : 5 1.7 - 2.2 (m, 6H), 2.35 (m, 1H), 3.15 - 3.5 (m, 7H), 3.9 (m, 1H), 4.05 (t, 2H), 4.45 (d, 2H), 5, 25 (m, 2H), 6.8 (d, 1H), 6.9 (m, 2H), 7.2 (m, 2H), 7.25 (t, 1H), 7.5 (m, 3H) ; MS [M-CF3C0O]+: 514.

Example 70 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(4-hydroxymethylphenoxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 17 mg , 16%. 'H- NMR (DMSO-d6) : 6 1.65 - 2.2 (m, 6H), 2.3 (m, 1H), 3.15 - 3.55 (m, 7H), 3.9 - 4.05 (m, 3H), 4.4 (d, 2H), 5.1 (t, OH), 5.25 (t, 1H), 6.9 (d, 2H), 7.0 (m, 2H), 7.2 (m, 2H), 7.25 (d, 2H), 7.5 (m, 3H); MS [M-CF3COO]+: 514.

Example 71 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(2-hydroxyphenoxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 24 mg , 19%. 'H- NMR (DMSO-d6) : b 1.65 - 2.15 (m, 6H), 2.35 (m, 1H), 3.2 (m, 1H), 3.25 - 3.55 (m, 6H), 3.95 (m, 1H), 4.0 (t, 2H), 5.25 (m, 1H), 6.7 -6.85 (m, 3H), 6.95 (d, 1H), 7.0 (m, 2H) 7.2 (m, 2H) 7.5 (m, 3H) 8.85 (s, OH); MS [M-CF3COO]+:
500.

Example 72 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(4-hydroxyphenoxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 16 mg , 15%. 'H- NMR (DMSO-d6) : 5 1.65 -2.1 (m, 6H), 2.3 (m, 1H), 3 . 2 ( m , 1H), 3.25 - 3. 5(m, 6H), 3.95 (m, 3H), 5.25 (m, 1H), 6.7 (d, 2H), 6.75 (d, 2H), 7.0 (m, 2H), 7.2 (m, 2H), 7.5 (t, 3H), 9.0 (s, OH); MS [M-CF3COO]+: 500.

Example 73 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-hydroxyphenoxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 16 mg , 15%. 'H- NMR (DMSO-d6) : 5 1.65 - 2.15 (m, 6H), 2.3 (m, 1H), 3.2 (m, 1H), 3.3 -3.55 (m, 6H), 3.9 - 4.0 (m, 3H), 5.25 (m, 1H), 6.9 -6.0 (m, 3H), 7.0 - 7.1 (m, 3H), 7.2 (m, 2H), 7.5 (m, 3H), 9.45 (s, OH); MS [M-CF3COO]+: 500.

Example 74 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-pyrrol-1-ylpropyl)-1-a zoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 21 mg , 22%. 'H- NMR (DMSO-d6) : 5 1.65-1.8 (m, 2H) , 1.8-2.0 (m, 2H) , 2.0 - 2.15 (m, 2H) 2.3 (m, 1H) 3.05-3.2 (m, 3H), 3.2-3.5 (m, 4H), 3.8-3.95 (m, 3H), 5.2 (m, 1H), 6.05 (t, 2H), 6.75 (t, 2H), 7.0 (t, 2H), 7.15 (d, 2H), 7.55 (m, 3H) ;MS [M-CF3COO]+: 457.

Example 75 3 (R) - (2-Hydroxy-2,2-dithien-2-ylacetoxy) -1- (4-oxo-4-thien-2- ylbutyl) -1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 18 mg , 17%. 'H- NMR (DMSO-d6) : 5 1.7-1.85 (m, 2H), 1.9-2.1 (m, 4H), 2.3 (m, 1H), 3.1 (t, 2H), 3.15-3.55 (m, 7H), 3.95 (m, 1H), 5.25 (m, 1H), 7.0 (t, 2H), 7.4 (d, 2H), 7.25 (t, 1H), 7.55 (m, 3H), 7.95 (d, 1H), 8.05 (d, 1H); MS [M-CF3COO]+: 502.

Example 76 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(1-methyl-[1H]-imidazol-2-ylsulfanyl)propyl]-1-azoniabicyclo[2.2.2]octane;
trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 26 mg , 25%. 'H- NMR (DMSO-d6): 5 1.7 (m, 2H), 1.85 - 2.05 (m, 4H), 2.3 (m, 1H), 3.25 - 3.5 (m, 7H), 3.6 (s, 3H), 3.9 (m, 1H), 4.2 (t, 2H), 5.2 (m, 1H), 7.0 (m, 3H), 7.15 (m, 2H), 7.3 (m, 1H), 7.5 (m, 3H); MS [M-CF3COO] 504.

Example 77 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(2-thien-2-ylethyl)-1-azo niabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 430 mg , 54%. 'H- NMR (DMSO-d6) : 5 1, 6-1 . 8 (m, 2H), 2,3 (m, 1H), 3,15-3,3 (m, 4H), 3.35-3.55(m, 5H), 3,95 (m, 1H), 5,25 (m, 1H) , 7,0 (m, 4H) 7,15 (m, 2H), 7.4-7,5 (m, 4H) ; MS [M-Br]+:
460; mp 206 C.

Example 78 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-thien-2-ylpropyl)-1-az oniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 600 mg , 77%. 'H- NMR (DMSO-d6) : 5 1.6 -1.8 (m, 2H), 1.85 - 2.1 (m, 4H), 2.3 (m, 1H), 2.8 (t, 2H), 3.1 - 3.5 (m, 7H), 3.9 (m, 1H), 5.2 (m, 1H), 6.9 - 7.05 (m, 4H), 7.15 (m, 2H), 7.4 (d, 1H), 7.5 (m, 3H) ; MS [M-Br] +: 474; mp 138 C.

Example 79 1-[3-(Benzothiazol-2-yloxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 23 mg , 21%. 'H- NMR (DMSO-d6) : b 1.65 - 2.1 (m, 6H), 2.3 (m, 1H), 3.15 (m, 1H), 3.25 - 3. 5(m, 6H), 3.85 (m, 1H), 4.0 (t, 2H), 5.2 (m, 1H), 7.0 (t, 2H), 7.15 (m, 2H), 7.25 (m, 1H), 7.45 (m, 5H), 7.7 (d, 1H); MS [M-CF3COO]+: 541.

Example 80 1-(3-Benzyloxypropyl)-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo[2.2.2] octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 16 mg , 15%. 'H- NMR (DMSO-d6) : b 1.65 (m, 2H), 1.9 (m, 4H), 2.3 (m, 1H), 3.1 - 3.4 (m, 7H), 3.5 (t, 2H), 3.9 (m, 1H), 3.9 (s, 2H), 5.2 (m, 1H), 7.0 (m, 2H), 7.15 (m, 2H), 7.35 (m, 5H), 7.5 (m, 3H); MS [M-CF,COO]+: 498.

Example 81 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[6-(4-phenylbutoxy) hexyl]-1-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 560 mg , 60%. 'H- NMR (CDC13) : b 1.2 -1.75 (m, 16H), 1.8 - 2.1 (m, 4H), 2.4 (m, 1H), 2.6 (t, 2H), 3.3 - 3.75 (m, 11H), 4.2 (m, 1H), 5.3 (m, 1H), 6.0 (bs, OH), 6.95 (m, 2H), 7.15 - 7.3 (m, 9H); MS [M-Br]+: 582.
Example 82 3 (R) - (2-Hydroxy-2,2-dithien-2-ylacetoxy) -1- (4-phenoxybutyl) -1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 240 mg , 30%. 'H- NMR (DMSO-d6/CDC13): b 1.8 - 1.95 (m, 6H), 2.1 (m, 2H), 2.45 (m, 1H), 3.18 (m, 1H), 3.5 - 3.8 (m, 6H), 4.0 (t, 2H), 4.15 (m, 1H), 5.15 (m, 1H), 6.7 (s, OH), 6.9 (m, 5H), 7.15 (d, 1H), 7.25 (m, 5H); MS [M-Br]+: 498; mp 161 C.
Example 83 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 380 mg , 50%. 'H- NMR (DMSO-d6) : b 1.85 (m, 5 2H), 2.05 (m, 2H), 2.4 (m, 1H), 3. 6- 4.1 (m, 7H), 4.35 (m, 3H), 5.25 (m, 1H), 6.0 (bs, OH), 6.9 (m, 4H), 7.0 (t, 1H), 7.1 (dd, 2H), 7.2 (dd, 2H), 7.3 (t, 2H); MS [M-Br]+: 470; mp 48 C.

Example 84 10 1- (2-Benzyloxyethyl) -3 (R) - (2-hydroxy-2,2-dithien-2-ylacetoxy) -1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 17 mg , 170. 'H- NMR (DMSO-d6) 5 1.65 - 2.0 (m, 4H), 2.3 (m, 1H), 3.2 - 3.55 (m, 7H), 3.85 (m, 2H), 4.5 (s, 15 2H), 5.25 (m, 1H), 7.0 (t, 2H), 7.15 (t, 2H), 7.3 - 7.4 (m, 4H), 7.5 (m, 3H) ; MS [M-CF3COO]': 484.

Example 85 3(S)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-20 azoniabicyclo[2.2.2] octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 600 mg , 54%. 1H- NMR (DMSO-d6/CDC13): 5 1.85 - 2.3 (m, 6H) , 2.5 (m, 1H) , 3.3 (m, 1H) , 3.4 (d, 1H) , 3.5 - 3.7 (m, 5H), 4.05 (t, 2H), 4.2 (m, 1H), 5.25 (m, 1H), 6.85 (d, 2H), 7.0 25 (m, 3H), 7.15 (m, 2H), 7.2 (d, 1H), 7.3 (m, 4H); MS [M-Br]': 484;
mp 230 C.

Example 86 4-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azonia 30 bicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods f and a. The yield of final step was 290 mg, 60%. 'H- NMR (DMSO-d6) : 5 2. 15 (m, 2H) , 2.35 (m, 6H), 3.35 (m, 2H), 3.65 (m, 6H), 4.05 (t, 2H), 6.9 - 7.05 (m, 5H), 7.1 (m, 2H), 7.3 (m, 3H), 7.55 (m, 2H); MS [M-Br]+:484; mp 168 C.

Example 87 4-(2-Hydroxy-2,2-dithien-2-yl-acetoxy)-1-phenethyl-l-azoniabicyclo[2 .2.2]octane; bromide The title compound was synthesised according to methods f and a. The yield of final step was 260 mg, 57%. 'H- NMR (DMSO-d6) : b 2.35 (m, 6H), 3.0 (m, 2H), 3.4 (m, 2H), 3.75 (m, 6H),7.0 (m, 2H), 7.3 - 7.5 (m, 6H), 7.55 (m, 2H); MS [M-Br]+:454; mp 195 C.

Example 88 1-(3-phenoxypropyl)-3(R)-(2,2-dithien-2-ylpropionyloxy)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 390 mg , 92%. 'H- NMR (DMSO-d6): b 1.65-2.20 (m, 6H), 2.10 (s, 3H), 2.30 (bs, 1H), 3.10 (m, 1H), 3.30-3.60 (m, 6H), 3.95-4.10 (m, 3H), 5.20 (m, 1H), 6.90-7.05 (m, 5H), 7.05-7.10 (m, 2H), 7.25-7.35 (m, 2H), 7.50 (m, 2H); MS [M-Br]+: 482; mp 170 C.

Example 89 3(R)-(2-Hydroxy-2,2-dithien-3-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 300 mg, 76%. 'H- NMR (DMSO-d6): 5 1.6 (m, 1H), 1.75 (m, 1H), 1.8 - 2.0 (m, 2H), 2.0 - 2.2 (m, 2H), 2.3 (m, 1H), 3.15 (m, 1H), 3.3 - 3.6 (m, 6H), 3.9 (m, 1H), 4.05 (t, 2H), 5.2 (m, 1H), 6.75 (s, OH), 6.95 (m, 3H), 7.15 (m, 2H), 7.3 (t, 2H), 7.4 - 7.5 (m, 4H); MS [M-Br]': 484; mp 219 C.

Example 90 3(R)-(2-Hydroxy-2,2-dithienyl-3-ylacetoxy)-1-(3-thien-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 300 mg, 77%. 'H- NMR (DMSO-d6) : 6 1.5-1.6 (m, 1H), 1.6-1.75 (m, 1H), 1.8-2.1 (m, 4H), 2.25 (m, 1H), 2.8 (t, 2H), 3.05-3.5 (m, 7H), 3.8-3.95 (m, 1H), 5,15 (m, 1H), 6.75 (s, OH), 6.9-7.0 (m, 2H), 7.1 (m, 2H), 7.35-7.55 (m, 5H); MS [M-Br]+: 474 ; mp 192 C.

Example 91 3(R)-(2-Hydroxy-2,2-dithien-3-yl-acetoxy)-1-phenethyl-l-azoniabicyclo [2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 63 mg, 48%. 'H- NMR (DMSO-d6): 6 1.5-1.7 (m, 1H), 1.7-1.85 (m, 1H), 1.9-2.1 (m, 2H), 2.3 (m, 1H), 2.9-3.1 (m, 2H), 3.15-3.6 (m, 7H), 3.9-4.0 (m, 1H), 5.2 (m, 1H), 6.8 (s, OH), 7.1 (m, 2H) , 7.25-7,35 (m, 5H), 7.4 (m, 2H) , 7.5 (m, 2H) ; MS [M-CF3COO] ': 454.
Example 92 3 (R) - (2-Hydroxy-2,2-dithien-3-yl-acetoxy) -1- (3-phenylpropyl) -1-azonia bicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 75 mg, 55%. 'H- NMR (DMSO-d6): 6 1.5-2.0 (m, 6H), 2.25 (m, 1H), 2.5-2.6 (m, 2H), 3.05-3.6 (m, 8H), 3.8-3.9 (m, 1H), 5.15(m, 1H), 6.75 (s, OH), 7.1 (d, 2H), 7.2-7,35 (m, 5H), 7.4 (m, 2H), 7.5 (m, 2H); MS [M-CF3COO468.
Example 93 3 (R) - (2-Hydroxy-2,2-dithien-3-ylacetoxy) -1- (4-phenylbutyl) -1-azoniab icyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 68 mg, 48%. 'H- NMR (DMSO-d6): b 1.5-1.8 (m, 6H), 1.8-2.0 (m, 2H), 2.25 (m, 1H), 2.6 (m, 2H), 3.05 (m, 1H), 3.15-3.45 (m, 6H), 3.85 (m, 1H), 5.15(m, 1H), 6.75 (s, OH), 7.1 (d, 2H), 7.2 (m, 2H), 7,3 (m, 3H), 7.4 (m, 2H), 7.5 (m, 2H); MS [M-CF3COO]+: 482.
Example 94 3(R)-(2-Hydroxy-2,2-dithien-3-ylacetoxy)-1-(2-thien-2-ylethyl)-1-azo niabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 65 mg, 49%. 'H- NMR (DMSO-d6) : 5 1.5-1.65 (m, 1H), 1.65-1.78 (m, 1H), 1.85-2.05 (m, 2H), 2.3 (m, 1H), 3.1-3.6 (m, 9H), 3.95 (m, 1H), 5,2 (m, 1H), 6.75 (s, OH), 7.0 (m, 2H), 7.15 (m, 2H), 7.45 (m, 3H), 7,5 (m, 2H); MS [M-CF3COO]+: 460.

Example 95 3(R)-(2-Hydroxy-2,2-dithien-3-ylacetoxy)-1-(4-phenoxybutyl)-1-azonia bicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 63 mg, 43%. 'H- NMR (DMSO-d6) : 5 1.5-2.0 (m, 8H), 2 . 3 ( m , 1H), 3. 1(m, 1H), 3.2-3. 5(m, 6H), 3.85 (m, 1H), 4.0 (m, 2H), 5.2(m, 1H), 6.75 (s, OH), 6.95 (m, 3H), 7.1 (d, 2H), 7.2 (m, 2H), 7,3 (t, 2H), 7.45 (m, 2H), 7.5 (m, 2H); MS [M-CF3COO]+: 498.
Example 96 3(R)-(2-Hydroxy-2,2-dithien-3-ylacetoxy)-1-(2-phenoxyethyl)-1-azonia bicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 72 mg, 52%. 'H- NMR (DMSO-d6) : 5 1.55-1.65 (m, 1H), 1.7-1.8 (m, 1H), 1.85-2.05 (m,2H), 2.3 (m, 1H), 3.2-3.6 (m, 5H), 3.7 (m, 2H), 4.05 (m, 1H), 4.4 (m, 2H), 5.2(m, 1H), 6.75 (s, OH), 6.95-7.05 (m, 3H), 7.1 (d, 2H), 7.3-7.5 (m, 6H); MS [M-CF3COO]+:
470.

Example 97 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-3-ylacetox y)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 79 mg, 54%. 'H- NMR (DMSO-d6) : 5 1.55-1.65 (m, 1H), 1.7-1.8 (m, 1H), 1.85-2.0 (m, 2H),2.05-2.2 (m, 2H), 2.3 (m, 1H), 3.1-3.2 (m, 1H), 3.25-3.55 (m, 6H), 3.85-3.95 (m, 1H), 4.0 (t, 2H), 5.2(m, 1H), 6.75 (s, OH), 6.95 (m, 2H), 7.15 (m, 4H), 7.4 (m, 2H), 7.5 (m, 2H); MS [M-CF3COO]': 502.

Example 98 3(R)-(2-Hydroxy-2,2-dithien-3-ylacetoxy)-1-(3-phenylallyl)-1-azoniab icyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 24 mg, 17%. 'H- NMR (DMSO-d6) : 6 1.8 - 2.05 (m, 4H), 2.3 (m, 1H), 3.15 (m, 1H), 3.3 - 3.5 (m, 4H), 3.9 (m, 1H), 4.05 (m 2H), 5.25 (m, 1H), 6.35 (m, 1H), 6.75 (s, OH), 6.85 (t, 1H), 7.1 (m, 2H), 7.3-7.5 (m, 5H), 7.55 (m, 4H); MS [M-CF3COO]+: 502.
Example 99 1-(3-phenylallyl)-3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 400 mg , 93%.'H- NMR (DMSO-d6) : 6 1. 35-1 . 50 (m, 1H), 1.60-1.75 (m, 1H), 1.75-1.95 (m, 2H), 2.10 (m, 1H), 2.85 (m, 1H), 3.10 (d, 1H), 3.20-3.50 (m, 3H) , 3.85 (m ,1H), 4.0 (dd, 2H) , 5.05 (m, 1H), 6.40 (dd, 1H), 6.80-6.90 (d, 1H), 6.85 (s, OH), 7.20-7.50 (m, 7H), 7.60 (m, 4H) , 7.80 (m, 2H) ; MS [M-Br]': 452; mp 146 C.

Example 100 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2] octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 690 mg , 83%. 'H- NMR (DMSO-d6) : b 1.47 (m, 1H), 1.68 (m, 1H), 1.87 (m, 2H), 2.1 (m, 3H), 2.89 (m, 1H), 3.15 (d, 1H), 3.4 (m, 5H), 3.9 (m, 1H), 4.0 (m, 2H), 5.04 (m, 1H), 6.85 (s, OH), 6.97 (m, 3H), 7.35 (m, 4H), 7.45 (m, 2H), 7.65 (m, 2H), 7.85 (m, 2H);
MS [M-Br] +: 470; mp 108 C.

Example 101 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-phenethyl-l-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 170 mg, 74%. 'H- NMR (DMSO-d6) : b 1.45 (m, 1H) , 1.65 (m, 1H), 1.85 (m, 2H), 2.1 (m, 1H), 2.9 (m, 3H), 3.15 (m, 1H), 3.3 - 3. 5(m, 5H), 3.85 (m, 1H), 5.05 (m, 1H), 6.85 (s, OH), 7.2 - 7.4 (m, 7H), 7.45 (t, 2H), 7.55 (d, 1H), 7.65 (d, 1H), 7.85 (d, 2H) ; MS [M-Br]': 440; mp 118 C.

Example 102 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-(2-phenoxyethyl)-1-5 azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 460 mg, 96%. 'H- NMR (DMSO-d6) : b 1.42 (m, 1H), 1.66 (m, 1H), 1.80-1.88 (m, 2H), 2.08 (m, 1H), 2.93 (m,1H), 3.25-3.60 (m, 4H), 3.65 (m, 2H), 3.95 (m, 1H), 4.35 (m , 2H), 5.02 (m, 1H), 6.85 10 (s, 1H, OH), 6.97 (d, 2H), 7.04 (t, 1H), 7.20-7.45 (m, 6H), 7.55-7.60 (t, 2H), 7.80 (d, 2H); MS [M-Br456; mp 140 C.

Example 103 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-(4-oxo-4-phenylbutyl) 15 -1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 15 mg, 15%. 'H- NMR (DMSO-d6) : b 1.45 (m, 1H), 1.65 (m, 1H), 1.7 - 2.0 (m, 4H), 2.1 (m, 1H), 2.75 (m, 1H), 3.0 -3.2 (m 4H), 3.25 - 3.4 (m, 4H), 3.85 (m, 1H), 5.05 (m, 1H), 6.85 20 (s, OH), 7.35 (t, 2H), 7.45 (t, 2H), 7.55 -7.7 (m, 5H), 7.85 (d, 2H), 8.0 (d, 2H); MS [M-CF3COO] ': 482.

Example 104 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(9-hydroxy-9[H]-fluorene-9-25 carbonyloxy)-1-azoniabicyclo[2.2.2]octane; chloride The title compound was synthesised according to methods c and a. The yield of final step was 440 mg, 94%. 'H- NMR (DMSO-d6) : b 1.4 (m, 1H), 1.65 (m, 2H), 1.7 - 1.95 (m, 2H), 2.0 - 2.1 (m, 3H), 2.8 (m, 1H), 3.1 (d, 1H), 3.2 - 3.4 (m, 5H), 3.8 (m, 1H), 4.0 (t, 2H), 5.0 (m, 30 1H), 6.85 (s, OH), 6.95 (m, 2H), 7.15 (t, 2H), 7.35 (t, 2H), 7.45 (t, 2H), 7.55 (d, 1H), 7.65 (d, 1H), 7.85 (d, 2H); MS [M-Br]': 488;
mp 142 C .

Example 105 35 1-[3-(2,4-Difluorophenoxy)propyl]-3(R)-(9-hydroxy-9[H]-fluorene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 14 mg, 13%. 'H- NMR (DMSO-d6): b 1.4 (m, 1H), 1.6 - 1.9 (m, 3H), 2.1 (m, 3H), 2.8 (m, 1H), 3.1 (d, 1H), 3.2 - 3.4 (m, 5H), 3.85 (m, 1H), 4.05 (t, 2H), 5.0 (m, 1H), 6.85 (s, OH), 7.05 (t, 1H), 7.15 - 7.4 (m, 4H), 7.45 (t, 2H), 7.55 (d, 1H), 7.65 (d, 1H), 7.85 (d, 2H); MS [M-CF3COO] ': 506.

Example 106 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-(3-phenylaminopropyl) -1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 14 mg, 15%. 'H- NMR (DMSO-d6) : b 1.4 (m, 1H), 1.6 (m, 1H), 1.8 (m, 4H), 2.05 (m, 1H), 2.7 (m, 1H), 3, 0 (m, 3H), 3.2 - 3.4 (m, 6H), 3.8 (m, 1H), 5.0 (m, 1H), 5.6 (t, NH), 6.55 (m, 3H), 6.85 (s, OH), 7.1 (t, 2H), 7.35 (dd, 2H), 7.45 (dd, 2H), 7.55 (dd, 2H), 7.8 (d, 2H) ; MS [M-CF3COO]+: 469.

Example 107 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-[3-(4-hydroxyphenoxy) propyl]-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 15 mg, 15%. 'H- NMR (DMSO-d6) : b 1.4 (m, 1H), 1.6 (m, 1H), 1.7 - 1.9 (m, 2H), 1.95 - 2.05 (m, 2H), 2.1 (m, 1H), 2.8 (m, 1H), 3 . 1 ( d , 1H), 3.25 - 3 . 4 ( m , 5H) , 3 . 8 - 3. 9(m, 3H), 5.0 (m, 1H), 6.7 (d, 2H), 6.75 (d, 2H), 6.85 (s, OH), 7.35 (t, 2H), 7.45 (t, 2H), 7.55 (d, 1H), 7.65 (d, 1H), 7.85 (d, 2H), 9.0 (s, OH) ; MS [M-CF3COO] +: 486.

Example 108 1- (2-Benzyloxyethyl) -3 (R) - (9-hydroxy-9 [H] -f luorene-9-carbonyloxy) -1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 470 mg, 96%. 'H- NMR (DMSO-d6) : b 1.4 (m, 1H), 1.65 (m, 1H), 1.7 - 1.9 (m, 2H), 2.1 (m, 1H), 2.9 (m, 1H), 3.15 -3.5 (m, 6H) 3.75 (m, 2H), 3.85 (m, 1H), 4.5 (s, 2H) 5.0 (m, 1H), 6.85 (s, OH), 7.3 - 7.5 (m, 9H), 7.55 (m, 2H), 7.8 (d, 2H);
MS [M-Br]+: 470; mp 86 C.
Example 109 3 (R) - (9-Hydroxy-9H-f luorene-9-carbonyloxy) -1- (3-thienyl-2-ylpropyl) -1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 180 mg, 70%. 'H- NMR (DMSO-d6) : 5 1.37 (m, 1H), 1.62 (m, 1H), 1.75-1.95 (m, 4H), 2.06 (m, 1H), 2.72 (m, 1H), 2.80 (m, 2H), 3.02-3.06 (m, 1H), 3.15-3.20 (m, 2H), 3.25-3.40 (m, 3H), 3.80 (m, 1H) , 5.0 (m, 1H), 6.85 (s, 1H, OH), 6.95-7.0 (m, 2H) , 7.25-7.50 (m, 5H), 7.55-7.65 (m, 2H), 7.85 (d, 2H); MS [M-Br]+: 460; mp 140 C.

Example 110 3 (R) - (9-Hydroxy-9H-f luorene-9-carbonyloxy) -1- (3-phenylpropyl) -1-azon iabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 80 mg, 40%. 'H- NMR (DMSO-d6) : 5 1.35 (m, 1H), 1.6 (m, 1H), 1.7-1.90 (m, 2H), 2.05 (m, 1H), 2.5 (m, 2H), 2.7 (m, 1H), 3.0 (m, 1H), 3.15 (m, 2H), 3.2-3.4 (m, 3H), 3.75 (m, 1H), 5.0 (m, 1H), 6.85 (s, OH), 7.20-7.50 (m, 9H), 7.55 (dd, 2H), 7.85 (d, 2H); MS [M-CF3C0O]+: 454.

Example 111 3(R)-(9-Hydroxy-9H-fluorene-9-carbonyloxy)-1-(4-phenylbutyl)-1-azoni abicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 74 mg, 35%. 'H- NMR (DMSO-d6) : 5 1.35 (m, 1H), 1.45-1.65 (m, 5H), 1.7-1.90 (m, 2H), 2.05 (m, 1H), 2.55-2.75 (m, 3H), 3.0 (m, 1H), 3.15 -3.45 (m, 5H), 3.75 (m, 1H), 5.0 (m, 1H), 6.85 (s, OH), 7.20 (m, 3H), 7.25 - 7.35 (m, 4H) 7.45-7.5 (m, 2H), 7.55-7.6 (dd, 2H), 7.85 (d, 2H); MS [M-CF3CO0]+: 468.

Example 112 3 (R) - (9-Hydroxy-9H-f luorene-9-carbonyloxy-l- (2-thienyl-2-ylethyl) -1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 79 mg, 39%. 'H- NMR (DMSO-d6) : 5 1.4 (m, 1H), 1.65 (m, 1H), 1.8-1.95 (m, 2H), 2.1 (m, 1H), 2.9 (m, 1H), 3.1-3.25 (m, 4H), 3.15 -3.45 (m, 5H) , 3.85 (m, 1H), 5.05 (m, 1H), 6.85 (s, OH), 7.0 (m, 2H), 7.35 (t, 2H), 7.45-7.5 (m, 3H), 7.55 (d, 1H), 7.65 (d, 1H), 7.85 (d, 2H); MS[M-CF3COO]+:446.

Example 113 3(R)-(9-Hydroxy-9H-fluorene-9-carbonyloxy)-1-(4-phenoxybutyl)-1-azon iabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 72 mg, 33%. 'H- NMR (DMSO-d6) : 5 1.4 (m, 1H), 1.55-1.9 (m, 7H), 2.05 (m, 1H), 2.7 (m, 1H), 3.0 (m, 1H), 3.15 -3.5 (m, 7H), 3.8 (m, 1H), 4.0 (m, 2H), 5.05 (m, 1H), 6.85 (s, OH), 6.95 (m, 3H), 7.25-7.35 (m, 4H), 7.4-7.45 (m, 2H), 7.6 (dd, 2H), 7.85 (d, 2H); MS [M-CF3COO]+: 484.

Example 114 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(3-phenylallyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 200 mg , 76%.'H- NMR (DMSO-d6) : 5 1.54 (m, 1H), 1.70-1.86 (m, 3H), 1.76 (s, 3H), 2.13 (m, 1H), 3.06 (m, 1H), 3.20-3.50 (m, 4H), 3.86 (m, 1H), 4.05 (dd, 2H), 5.02 (m, 1H), 6.43 (dd, 1H), 6.86 (d, 1H), 7.26-7.46 (m, 7H), 7.58-7.65 (m, 3H), 7.70-7.72 (m, 1H), 7.87-7.90 (m, 2H); MS [M-Br]': 450; mp 234 C.
Example 115 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(2-phenoxyethyl)-1-azo niabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 210 mg , 66o.1H- NMR (DMSO-d6) : 5 1.55 (m, 1H), 1.60-2.0 (m, 3H), 1.76 (s, 3H), 2.12 (m, 1H), 3.10-3.25 (m, 1H), 3.40-3.80 (m, 6H) , 4.0 (m, 1H) , 4.41 (m, 2H) , 4.98 (m, 1H) , 6.98-7.05 (m, 3H), 7.27-7.46 (m, 6H), 7.63-7.71 (m, 2H), 7.87-7.90 (m, 2H); MS
[M-Br]': 454; mp 202 C.
Example 116 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 210 mg , 61o.1H- NMR (DMSO-d6) : 5 1.55 (m,1H), 1.60-2.0 (m, 3H), 1.78 (s, 3H), 2.0-2.20 (m, 3H), 3.0-3.10 (m,1H), 3.25-3.53 (m, 6H), 3.86 (m, 1H), 4.03 (m, 2H), 4.98 (m, 1H), 6.95- 7.0 (m, 3H), 7.30-7.48 (m, 6H), 7. 65-7. 92 ( m, 4H) ; MS [M-Br]': 468; mp 204 C .

Example 117 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-phenethyl-l-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 18 mg, 19%. 'H- NMR (DMSO-d6) : 5 1.55 (m, 1H), 1.65 - 1.95 (m, 3H), 1.75 (s, 3H), 2.15 (m, 1H), 2.9 - 3.1 (m, 4H), 3.25 - 3.55 (m, 5H), 3.85 (m, 1H), 5.05 (m, 1H), 7.25 - 7.55 (m, 9H), 7.65 (d, 1H), 7.75 (d, 1H), 7.95 (d, 2H); MS [M-CF3COO]+: 438.
Example 118 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(4-oxo-4-phenylbutyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg, 19%. iH- NMR (DMSO-d6) : 5 1.55 (m, 1H), 1.65 - 2.05 (m, 5H), 1.75 (s, 3H), 2.1 (m, 1H) 3.0 (m, 1H), 3.1 - 3.5 (m, 8H), 3.85 (m, 1H), 7.35 - 7.5 (m, 4H), 7.55 (t, 2H), 7.65 (t, 2H), 7.7 (d, 1H), 7.9 (d, 2H), 8.0 (d, 2H); MS [M-CF3COO]+: 480.
Example 119 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(9-methyl-9[H]-fluorene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 23 mg, 23%. iH- NMR (DMSO-d6) : b 1.55 (m, 1H), 1.65 - 1.95 (m, 3H), 1.75 (s, 3H), 2.05 - 2.15 (m, 3H), 3.0 (m, 1H), 5 3.25 - 3.5 (m, 6H), 3.85 (m, 1H), 4.0 (t, 2H), 5.0 (m, 1H), 6.95 (m, 2H), 7.15 (t, 2H), 7.35 - 7.5 (m, 4H), 7.65 (d, 1H), 7.75 (d, 1H), 7.9 (d, 2H) ; MS [M-CF3COO] ': 486.

Example 120 10 1-[3-(2,4-Difluorophenoxy)propyl]-3(R)-(9-methyl-9H-fluorene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 20 mg, 19%. 'H- NMR (DMSO-d6) : b 1.55 (m, 1H), 1.65 - 1.95 (m, 3H), 1.75 (s, 3H), 2.05 - 2.2 (m, 3H), 3.0 (m, 1H), 15 3.25 - 3.55 (m, 6H), 3.85 (m, 1H), 4.1 (t, 2H), 5.0 (m, 1H), 7.05 (t, 1H), 7.2 - 7.5 (m, 6H), 7.65 (d, 1H), 7.75 /d, 1H), 7.9 (d, 2H) ; MS [M-CF3COO]+: 504.

Example 121 20 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(3-phenylaminopropyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg, 19%. 'H- NMR (DMSO-d6) : 5 1.55 (m, 1H), 1.65 - 1.95 (m, 5H), 1.75 (s, 3H), 2.1 (m, 1H), 2.95 (m, 1H), 3.05 25 (m, 2H), 3.15 - 3.45 (m, 6H), 3.8 (m, 1H), 5.0 (m, 1H), 5.65 (t, NH), 6.6 (m, 3H), 7.1 (t, 2H), 7.35 - 7.55 (m, 4H), 7.65 (d, 1H), 7.75 (d, 1H), 7.9 (d, 2H); MS [M-CF3COO]+: 467.

Example 122 30 1-[3-(4-Hydroxyphenoxy)propyl]-3(R)-(9-methyl-9[H]-fluorene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 22 mg, 22%. 'H- NMR (DMSO-d6) : 5 1.55 (m, 1H), 1.65 - 1.9 (m, 3H), 1.75 (s, 3H), 2.0 - 2.15 (m, 3H), 3.0 (m, 1H), 35 3.25 - 3.5 (m, 6H), 3.8 - 3.95 (m, 3H), 5.0 (m, 1H), 6.7 (d, 1H), 6.75 (d, 1H), 7.35 - 7.45 (m, 4H), 7.65 (d, 1H), 7.75 (d, 1H), 7.9 (d, 2H), 9.0 (s, OH) ; MS [M-CF3COO]': 484.

Example 123 1-(2-Benzyloxyethyl)-3(R)-(9-methyl-9[H]-fluorene-9-carbonyloxy)-1-a zoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 17 mg, 17%. 'H- NMR (DMSO-d6) : b 1.55 (m, 1H), 1.65-1.95 (m, 4H), 1.75 (s, 3H), 2.15 (m, 1H), 3.1 (m, 1H), 3.3-3.55 (m, 6H), 3.8-3.95 (m, 3H), 4.5 (s, 2H), 5.0 (m, 1H), 7.3-7.5 (m, 9H), 7.6-7.7 (m, 2H), 7.9 (d, 2H); MS [M-CF3COO]+: 468.

Example 124 3(R)-(9,10-Dihydroanthracene-9-carbonyloxy)-1-phenethyl-l-azoniabicy clo[2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 420 mg , 89%.'H- NMR (DMSO-d6) : b 1.55 (m, 1H), 1.65-1.95 (m, 3H), 2.15 (m, 1H), 2.95 (m, 2H), 3.15 (m, 1H), 3.25-3.60 (m, 6H), 3.85 (m, 1H), 3.95-4.15 (dd, 2H, J1= 1.8 Hz, J2= 4.2Hz), 5.02 (m, 1H), 5.25 (s, 1H), 7.25-7.43 (m, 11H), 7.48-7.55 (m, 2H); MS [M-Br]+: 438; mp 216 C.

Example 125 3 (R) - (9, 10-Dihydroanthracene-9-carbonyloxy) -1- (3-phenoxypropyl) -1-az oniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 450 mg , 82 0.1H- NMR (DMSO-d6) : b 1. 56 (m, 1H) , 1.65-1.95 (m, 3H), 2.05-2.15 (m, 3H), 3.10 (m, 1H), 3.20-3.50 (m, 6H), 3.80 (m, 1H) , 3.94-4.14 (m, 4H) , 5.0 (m, 1H), 5.22 (s, 1H) , 6.94-7.0 (m, 3H), 7.25-7.35 (m, 6H), 7.40 (m, 2H), 7.54-7.47 (m, 2H); MS [M-Br]': 468; mp 157 C.

Example 126 1-(4-Phenylbutyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 83 mg , 21%.'H- NMR (DMSO-d6) : b 1.50-2.0 (m, 8H), 2.15 (m, 1H), 2.65 (m, 2H), 3.05-3.65 (m, 7H), 3.80 (m, 1H), 5.0 (m, 1H), 5.30 (s, 1H), 7.10-7.45 (m, 11H), 7.45-7.60 (m, 2H); MS [M-Br]': 468; mp 95 C.

Example 127 1-(2-Phenoxyethyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 300 mg , 73%. 'H- NMR (DMSO-d6) : b 1.70-2.0 (m, 4H), 2.2 (m, 1H), 3.20-3.80 (m, 7H), 4.0 (m, 1H), 4.40 (m, 2H), 5.05 (m, 1H), 5.30 (s, 1H), 7.0-7.10 (m, 7H), 7.30-7.45 (m, 4H), 7.45-7.55 (m, 2H); MS [M-Br]+: 456; mp 200 C.

Example 128 1- (3-Phenoxypropyl) -3 (R) - (9 [H] -xanthene-9-carbonyloxy) -1-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 350 mg , 83%. 'H- NMR (DMSO-d6) : b 1.70-2.0 (m, 4H), 2.0-2.25 (m,3H), 3.15-3.65 (m, 7H), 3.85-3.95 (m, 1H), 3.95-4.10 (m, 2H), 5.0 (m, 1H), 5.30 (s, 1H), 6.90-7.0 (m, 3H), 7.10-7.25 (m, 4H), 7.25-7.40 (m, 4H), 7.40-7.60 (m, 2H); MS [M-Br]+: 470; mp 184 C.
Example 129 1-Phenethyl-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo [2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 100 mg, 44%. 'H- NMR (DMSO-d6) : b 1.65 - 2.0 (m, 4H), 2.1 (m, 1H), 2.9 - 3.05 (m, 2H), 3.15 - 3.6 (m, 7H), 3.85 (m, 1H), 5.05 (m, 1H), 5.3 (s, 1H)), 7.15 - 7.55 (m, 13H);
MS [M-Br]': 440.
Example 130 1-(4-Oxo-4-phenylbutyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azonia bicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods d and b. The yield of final step was 16 mg, 15%. 'H- NMR (DMSO-d6) : b 1.65 - 2.05 (m, 6H), 2.1 (m, 1H), 3.1 - 3.55 (m, 9H), 3.8 (m, 1H), 5.05 (m, 1H), 5.25 (s, 1H), 7.1 - 7.3 (m, 4H), 7.35 (t, 2H), 7.45 - 7.6 (m, 4H), 7.7 (d, 1H), 8.0 (d, 1H) ; MS [M-CF3COO]+: 482.

Example 131 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane, trifluoroacetate The title compound was synthesised according to methods d and b. The yield of final step was 18 mg, 18%. '-H- NMR (DMSO-d6) : b 1.7 - 2.1 (m, 6H), 2.15 (m, 1H), 3.1 - 3.5 (m, 7H), 3.8 (m, 1H), 4.0 (t, 2H), 5.0 (m, 1H), 5.3 (s, 1H), 6.95 (m, 2H), 7.1 - 7.3 (m, 6H), 7.4 (t, 2H), 7.5 (dd, 2H); MS [M-CF3COO]': 488.

Example 132 1-[3-(2,4-Difluorophenoxy)propyl]-3(R)-(9[H]-xanthene-9-carbonyloxy) -1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods d and b. The yield of final step was 14 mg, 140. 'H- NMR (DMSO-d6) : b 1.65 - 1.95 (m, 4H), 2.05 - 2.2 (m, 3H), 3.1 - 3.55 (m, 7H), 3.8 (m, 1H), 4.05 (t, 2H), 5.0 (m, 1H), 5.3 (s, 1H), 7.05 (t, 1H), 7.1 - 7.55 (m, 10H) ; MS [M-CF3COO] +: 506.

Example 133 1-(3-Phenylaminopropyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods d and b. The yield of final step was 17 mg, 17%. 'H- NMR (DMSO-d6) : b 1.65 - 2.0 (m, 6H), 2.15 (m, 1H), 3.0 - 3.5 (m, 9H), 1.75 (m, 1H), 5.0 (m, 1H), 5.3 (s, 1H), 6.65 (t, NH), 6.55 (m, 3H), 7.05 - 7.3 (m, 6H), 7.35 - 7.55 (m, 4H); MS [M-CF3COO]: 469.

Example 134 1-[3-(4-Hydroxyphenoxy)propyl]-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods d and b. The yield of final step was 21 mg, 20%. 'H- NMR (DMSO-d6) : b 1.7 - 2.1 (m, 6H), 2.15 (m, 1H), 3.1 - 3.5 (m, 7H), 3.7 - 3.95 (m, 3H), 5.0 (m, 1H), 5.3 (s, 1H), 6.7 (d, 2H), 6.75 (d, 2H), 7.1 - 7.3 (m, 4H), 7.35 - 7.55 (m, 4H), 9.0 (s, OH); MS [M-CF3COO]+: 486.

Example 135 1-(2-Benzyloxyethyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods d and b. The yield of final step was 16 mg, 16%. 'H- NMR (DMSO-d6) : 6 1.65 - 1.95 (m, 4H), 2.1 (m, 1H), 3.1 - 3.9 (m, 10H), 4.5 (s, 2H), 5.0 (m, 1H), 5.3 (s, 1H), 7.15 (m, 4H), 7.3 - 7.5 (m, 7H), 7.55 (t, 2H);
MS [M-CF3COO] +: 470.
Example 136 3(R)-(9-Hydroxy-9[H]-xanthene-9-carbonyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 340 mg , 71%. 'H- NMR (DMSO-d6): 5 1.30 (m, 1H), 1.65 (m, 1H), 1.70-1.95 (m, 2H), 1.95-2.10 (m, 3H), 2.70 (m, 1H), 2.90 (m, 1H), 3.2-3.5 (m, 5H), 3.80 (m, 1H), 4.0 (t, 2H), 5.05 (m, 1H), 6.90-7.0 (m, 3H), 7.20-7.35 (m, 7H), 7.40-7.46 (m, 2H), 7.65-7.70 (m, 2H); MS [M-Br]: 486; mp 219 C.

Example 137 3(R)-(9-Hydroxy-9[H]-xanthene-9-carbonyloxy)-1-phenethyl-l-azoniabi cyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 290 mg , 64%. 'H- NMR (DMSO-d6) : 5 1.32 (m, 1H), 1.65 (m, 1H), 1.70-1.95 (m, 2H), 2.1 (m, 1H), 2.75-2.90 (m, 3H), 3.05 (m, 1H), 3.30-3.50 (m, 5H), 3.82 (m, 1H), 5.05 (m, 1H), 7.20-7.40 (m, 10H) , 7.40-7.50 (m, 2H) , 7. 65-7.70 (m, 2H) ; MS [M-Br]': 456; mp 221 C.

Example 138 3 (R) - (9-Hydroxy-9H-xanthene-9-carbonyloxy) -1- (3-thien-2-ylpropyl) -1-5 azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 310 mg , 97%. 'H- NMR (DMSO-d6) : 5 1.30 (m, 1H), 1.62 (m, 1H), 1.70-1.90 (m, 4H), 2.05 (m,1H), 2.60 (m, 1H), 2.75-2.85 (m, 4H), 3.15 (m, 2H), 3.25-3.40 (m, 2H), 3.75 (m, 1H), 5.0 10 (m, 1H), 6.93 (m,1H), 7.0 (m, 1H), 7.14-7.26 (m, 5H), 7.36-7.45 (m, 3H), 7.63-7.67 (m, 2H); MS [M-Br]': 476; mp 111 C.

Example 139 3(R)-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-1-(3-phenylpropyl)-1-azo 15 niabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 85 mg , 41%. 'H- NMR (DMSO-d6) : b 1.30 (m, 1H), 1.65 (m, 1H), 1.70-1.95 (m, 2H), 2.05 (m, 1H), 2.5-2.6 (m, 2H), 2.80 (m, 1H), 3.05-3.75 (m, 7H), 5.05 (m, 1H), 7.1-7.45 (m, 12H), 20 7.65-7.70 (m, 2H); MS [M-CF3COO]': 470.

Example 140 3(R)-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-1-(4-phenylbutyl)-1-azoni abicyclo[2.2.2]octane; trifluoroacetate 25 The title compound was synthesised according to methods c and b. The yield of final step was 84 mg , 38%. 'H- NMR (DMSO-d6) : b 1.30 (m, 1H), 1.4-1.85 (m, 7H) , 2.05 (m, 1H) , 2.5-2.6 (m, 2H), 2.80 (m, 1H), 3.05-3.4 (m, 6H), 3.7 (m, 1H), 5.05 (m, 1H), 7.15-7.35 (m, 10H), 7.4 (m, 1H), 7.65 (m, 2H); MS [M-CF3COO]+: 484.
Example 141 3(R)-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-1-(2-thien-2-ylethyl)-1-a zoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 81 mg , 39%. 'H- NMR (DMSO-d6) : 5 1.30 (m, 1H), 1.6 (m, 1H) , 1.7-1.9(m, 2H) , 2.05 (m, 1H) 2.75(m, 1H), 3.0(m, 1H), 3.1-3.2 (m, 2H), 3.3-3.6 (m, 5H), 3.8 (m, 1H), 5.05 (m, 1H), 6.95-7.0 (m, 2H) , 7.15-7.3 (m, 5H), 7.45 (m, 3H), 7.65 (m, 2H); MS [M-CF3COO]
462.
Example 142 3(R)-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-1-(4-phenoxybutyl)-1-azo niabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 83 mg , 37%. 'H- NMR (DMSO-d6) : b 1.3 (m, 1H), 1.5-1.9 (m, 7H), 2.05 (m, 1H), 2.6 (m, 1H), 2,8 (m, 1H), 3.1-3.45 (m, 7H), 3.75 (m, 1H), 4.0 (m, 2H), 5.05 (m, 1H), 6.95-7.0 (m, 3H), 7.15-7.45 (m, 9H), 7.65 (m, 2H); MS [M-CF3COO]+: 500.

Example 143 3(R)-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-1-(2-phenoxyethyl)-1-azo niabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 102 mg , 48%. 'H- NMR (DMSO-d6) : 5 1. 3 (m, 1H) , 1.55-1.95 (m, 3H), 2.05 (m, 1H), 2,8 (m, 1H), 3.1 (m, 1H), 3.35-3.65 (m, 5H), 3.9 (m, 1H), 4.35 (m, 2H), 5.05 (m, 1H), 6.95 (d, 2H), 7.0-7.1 (m, 2H), 7 . 2 (m, 4H), 7.3-7.45 (m, 4H), 7. 6(t, 2H) ; MS [M-CF3COO]+: 472.

Exemple 144 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(9-hydroxy-9H-xanthene-9-carbonyl oxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 99 mg , 44%. 'H- NMR (DMSO-d6) : 5 1.3 (m, 1H), 1.6 (m, 1H), 1.7-2.0 (m, 4H), 2.05 (m, 1H), 2.7 (m, 1H), 2.9 (m, 1H), 3.2-3.5 (m, 5H), 3.75-3.85 (m, 1H), 3.95 (m, 2H), 5.0 (m, 1H), 6.95 (m, 2H), 7.1-7.3 (m, 7H), 7.45 (t, 2H), 7.65 (t, 2H); MS [M-CF3COO]+:
504.

Exemple 145 3 (R) - (9-Hydroxy-9H-xanthene-9-carbonyloxy) -1- (3-phenylallyl) -1-azoni abicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 25 mg , 12%. 1H- NMR (DMSO-d6) : b 1.25-1 . 30 (m, 1H), 1.55-1.95 (m, 3H), 2.10 (m, 1H), 2.65-2.75 (m, 1H), 2.9 (m, 1H), 3.25-3.50 (m, 2H), 3.75-3.8 (m ,1H), 3.95 (m, 2H), 4.2 (d, 1H), 5.0 (m, 1H), 6.35 (m, 1H), 6.80 (d, 1H), 7.05-7.50 (m, 8H), 7.60 (m, 4H); MS
[M-CF3COO]+: 468.

Example 146 3(R)-(9-Methyl-9[H]-xanthene-9-carbonyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods c and a. The yield of final step was 110 mg. 'H- NMR (DMSO-d6): b 1.4 (m, 1H), 1.65 (m, 1H) , 1.75 - 1.95 (m, 2H) , 1.9 (s, 3H) , 2.05 - 2.15 (m, 3H) , 1.8 (m, 1H), 3.15 (m, 2H), 3.25 - 3. 5(m, 5H), 3.85 (m, 1H), 4.0 (t, 2H), 5.05 (m, 1H), 6.95 - 7.0 (m, 3H), 7.15 - 7.2 (m, 4H), 7.3 -7.4 (m, 4H), 7.45 (d, 1H), 7.55 (d, 1H); MS [M-Br]+: 484; mp 195 C.
Example 147 3(R)-(9-Methyl-9[H]-xanthene-9-carbonyloxy)-1-phenethyl-l-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg, 200. 1H- NMR (DMSO-d6) : b 1.4 (m, 1H), 1.65 (m, 1H), 1.8 - 1.95 (m, 2H), 1.9 (s, 3H), 2.15 (m, 1H), 2.8 - 2.95 (m, 3H), 3.15 (d, 1H), 3.3 - 3.5 (m, 5H), 4.9 (m, 1H), 5.1 (m, 1H), 7.15 (m, 4H), 7.25 - 7.4 (m, 7H), 7.45 (d, 1H), 7.55 (d, 1H) ; MS [M-CF3COO]+: 454.

Example 148 3(R)-(9-Methyl-9[H]-xanthene-9-carbonyloxy)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 24 mg, 240. 'H- NMR (DMSO-d6) : b 1.4 (m, 1H), 1.65 (m, 1H), 1.8 - 1.95 (m, 2H), 1.9 (s, 3H), 2.15 (m, 1H), 2.95 (m, 1H), 3.25 (m, 1H), 3.4 - 3.65 (m, 5H), 3.85 (m, 1H), 4.35 (t, 2H), 5.05 (m, 1H), 6.95 (d, 2H), 7.05 (t, 2H), 7.15 (m, 3H), 7.25 - 7.45 (m, 6H) ; MS [M-CF3COO]+: 470.

Example 149 3(R)-(9-Methyl-9[H]-xanthene-9-carbonyloxy)-1-(4-oxo-4-phenylbutyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg, 19%. 'H- NMR (DMSO-d6) : 5 1.4 (m, 1H), 1.65 (m, 1H), 1.75 - 1.95 (m, 7H), 2.15 (m, 1H), 2.8 (m, 1H), 3.05 - 3.25 (m, 4H), 3.3 - 3.5 (m, 4H), 3.85 (m, 1H), 5.05 (m, 1H), 7.15 (m, 4H), 7.35 (t, 2H), 7.45 - 7.6 (m, 4H), 7.7 (t, 1H), 8.0 (d, 2H) ; MS [M-CFjCOO]': 496.

Example 150 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(9-methyl-9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 25 mg, 24%. 'H- NMR (DMSO-d6) : 5 1.4 (m, 1H), 1.65 (m, 1H), 1.75 - 1.95 (m, 2H), 1.9 (s, 3H), 1.95 - 2.1 (m, 2H), 2.15 (m, 1H), 2.8 (m, 1H), 3.1 (d, 1H), 3.25 - 3.5 (m, 5H), 3.8 (m, 1H), 4.0 (t, 2H), 5.05 (m, 1H), 6.95 (m, 2H), 7.15 (m, 6H), 7.35 (t, 2H), 7.5 (dd, 2H); MS [M-CF3COO]': 502.

Example 151 1-[3-(2,4-Difluorophenoxy)propyl]-3(R)-(9-methyl-9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 16 mg, 15%. 'H- NMR (DMSO-d6) 5 1.4 (m, 1H), 1.65 (m, 1H), 1.75 - 1.95 (m, 2H), 1.9 (s, 3H), 2.0 - 2.15 (m, 3H), 2.8 (m, 1H), 3.1 (d, 1H), 7.05 (t, 1H), 7.1 - 7.4 (m, 8H), 7.5 (dd, 2H); MS [M-CF3COO]+: 520.

Example 152 3(R)-(9-Methyl-9[H]-xanthene-9-carbonyloxy)-1-(3-phenylaminopropyl)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 16 mg, 15%. 'H- NMR (DMSO-d6) : b 1.35 (m, 1H), 1.6 (m, 1H), 1.7 - 1.9 (m, 4H), 1.9 (s, 3H), 2.1 (m, 1H), 2.7 (m, 1H), 2.95 - 3.05 (m, 3H), 3.1 - 3.4 (m, 6H), 3.75 (m, 1H), 5.0 (m, 1H), 5.6 (m, 1H), 6.55 (m, 3H), 7.05 - 7.15 (m, 6H), 7.3 (m, 2H), 7.45 (t, 2H); MS [M-CF3C0O]': 483.

Example 153 1-[3-(4-Hydroxyphenoxy)propyl]-3(R)-(9-methyl-9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 19 mg, 18%. '-H- NMR (DMSO-d6) : b 1.4 (m, 1H), 1.65 (m, 1H), 2.75 - 2.05 (m, 4H), 1.9 (s, 3H), 2.15 (m, 1H), 2.8 (m, 1H), 3.1 (d, 1H), 3.25 - 3.5 (m, 5H), 3.8 - 3.95 (m, 3H), 5.05 (m, 1H), 6.65 - 6.8 (m, 4H), 7.2 (m, 4H), 7.35 (t, 2H), 7.5 (m, 2H), 9.0 (s, OH); MS [M-CF3COO]+: 500.

Example 154 1-(2-Benzyloxyethyl)-3(R)-(9-methyl-9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; trifluoroacetate The title compound was synthesised according to methods c and b. The yield of final step was 14 mg, 140. 'H- NMR (DMSO-d6) : b 1.4 (m, 1H), 1.65 (m, 1H), 1.75 - 1.95 (m, 2H), 1.9 (s, 3H), 2.1 (m, 1H), 2.9 (m, 1H), 3.2 - 3.5 (m, 6H), 3.75 - 3.95 (m, 3H), 4.5 (s, 2H), 5.05 (m, 1H), 7.15 (m, 4H), 7.3 - 7.5 (m, 9H); MS [M-CF3COO] ': 484.

Example 155 1-(3-Phenoxypropyl)-3(R)-(9[H]-thioxanthene-9-carbonyloxy)-1-azonia-bicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 323 mg, 50%. 'H- NMR (DMSO-d6) : 5 1.35 (m, 1H), 1. 65 (m, 1H), 1.70-1.95 (m, 2H), 2.0-2.2 (m, 3H), 2.75-2.90 (m, 1H), 3,12 (m, 1H), 3.25-3.50 (m, 5H), 3.80 (m, 1H), 4.0 (t, 2H), 5.0 (m, 1H), 5.6 (s, 1H) , 6.94-7.0 (m, 3H), 7.22-7.41 (m, 6H), 7.45-7.64 (m, 4H); MS [M-Br]+: 486; mp 157 C.

Example 156 1- (3 -phenylallyl) - 3 (R) - (10, 11 -Dihydro-5H-dibenz o [ a, d]
cycloheptene - 5 -5 carbonyloxy)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 250 mg , 94%. 'H- NMR (CDC13) : 5 1.50-1.60 (m,1H), 1.60-1.80 (m,1H), 1.90 (m, 2H), 2.30 (m, 1H), 2.65-2.80 (m, 2H), 2.90-3.20 (m, 3H), 3.50 (d, 1H), 3.60-3.90 (m, 3H), 4.20 (m, 1H), 10 4.35-4.60 (doble dd, 2H), 5.10 (m, 1H), 5.15 (s, 1H), 6.05 (dd, 1H), 6.90-7.0 (m, 2H), 7.0-7.5 (m, 11H); MS [M-Br]': 464; mp 132 C.
Example 157 1-(3-phenoxypropyl)-3(R)-(10,11-Dihydro-5H-dibenzo[a,d]cycloheptene-15 5-carbonyloxy)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 290 mg , 94%. 'H- NMR (CDC13) : b 1.45-1.60 (m, 1H), 1.65-1.80 (m, 1H), 1.80-2.0 (m, 2H), 2.0-2.20 (m, 3H), 2.80-3.0 (m, 3H), 3.15-3.30 (m, 2H), 3.30-3.45 (d, 1H), 3.45-3.80 (m, 5H), 20 3.85-4.0 (m, 2H), 4.20 (m, 1H), 5.10 (m, 1H), 5.20 (s, 1H), 6.80-6.90 (d, 2H), 6. 90-7. 0(t, 1H), 7.10-7.30 (m, 8H), 7.40 (m, 2H) ; MS [M-Br]': 482; mp 182 C.

Example 158 25 3(R)-(5[H]-Dibenzo[a,d]cycloheptene-5-carbonyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 180 mg, 56%. 'H- NMR (DMSO-d6): b 1.2 (m, 1H), 1.6 (m, 1H), 1.7 - 1.9 (m, 2H), 1.95 (m, 1H), 2.1 (m, 2H), 2.8 (m, 30 1H), 2.95 (d, 1H), 3.25 - 3.45 (m, 5H), 3.8 (m, 1H), 4.05 (t, 2H), 4 . 9 ( m , 1H), 5.45 ( s , 1H), 6 . 9 - 7 . 1 (m, 5H) , 7 . 3 - 7. 5(m, 9H), 7.55 (d, 2H); MS [M-Br]': 480; mp 111 C.

Example 159 35 3(R)-(5[H]-Dibenzo[a,d]cycloheptene-5-carbonyloxy)-1-phenethyl-l-azoniabicyclo[2.2.2]octane; bromide The title compound was synthesised according to methods d and a. The yield of final step was 210 mg, 68%. 1H- NMR (DMSO-d6) : 5 1.2 (m, 1H), 1.7 - 1.9 (m, 2H), 2.0 (m, 1H), 2.85 - 3.1 (m, 4H), 3.3 - 3.5 (m, 5H), 3.85 (m, 1H), 4.95 (m, 1H), 5.45 (s, 1H), 7.05 (m, 2H), 7.25 - 7.5 (m, 11H), 7.55 (m, 2H); MS [M-Br]+: 450; mp 248 C.

The Examples 160 to 164 illustrate pharmaceutical compositions according to the present invention and procedure for their preparation.

Example 160 Preparation of a pharmaceutical composition: tablets Formulation:

Compound of the present invention ............ 5.0 mg Lactose ....................................... 113.6 mg Microcrystalline cellulose .................... 28.4 mg Light silicic anhydride ....................... 1.5 mg Magnesium stearate ............................ 1.5 mg Using a mixer machine, 15 g of the compound of the present invention was mixed with 340.8 g of lactose and 85.2 g of microcrystalline cellulose. The mixture was subjected to compression moulding using a roller compactor to give a flake-like compressed material. The flake-like compressed material was pulverized using a hammer mill, and the pulverized material was screened through a 20 mesh screen. A 4.5 g portion of light silicic anhydride and 4.5 g of magnesium stearate were added to the screened material and mixed. The mixer product was subjected to a tablets making machine equipped with a die/punch system of 7.5 mm in diameter, thereby obtaining 3,000 tablets each having 150 mg in weight.

Example 161 Preparation of a pharmaceutical composition: tablets coated Formulation:
Compound of the present invention ................. 5.0 mg Lactose ........................................... 95.2 mg Corn starch ....................................... 40.8 mg Polyvinylpyrrolidone K25 .......................... 7.5 mg Magnesium stearate ................................ 1.5 mg Hydroxypropylcellulose ............................ 2.3 mg Polyethylene glycol 6000 .......................... 0.4 mg Titanium dioxide .................................. 1.1 mg Purified talc ..................................... 0.7 mg Using a fluidized bed granulating machine, 15 g of the compound of the present invention was mixed with 285.6 g of lactose and 122.4 g of corn starch. Separately, 22.5 g of polyvinylpyrrolidone was dissolved in 127.5 g of water to prepare a binding solution. Using a fluidized bed granulating machine, the binding solution was sprayed on the above mixture to give granulates. A 4.5 g portion of magnesium stearate was added to the obtained granulates and mixed. The obtained mixture was subjected to a tablet making machine equipped with a die/punch biconcave system of 6.5 mm in diameter, thereby obtaining 3,000 tablets, each having 150 mg in weight.
Separately, a coating solution was prepared by suspending 6.9 g of hydroxypropylmethylcellulose 2910, 1.2 g of polyethylene glycol 6000, 3.3 g of titanium dioxide and 2.1 g of purified talc in 72.6 g of water. Using a High Coated, the 3,000 tablets prepared above were coated with the coating solution to give film-coated tablets, each having 154.5 mg in weight.

Example 162 Preparation of a pharmaceutical composition: liquid inhalant Formulation:
Compound of the present invention ............. 400 /ig Physiological saline .......................... 1 ml A 40 mg portion of the compound of the present invention was dissolved in 90 ml of physiological saline, and the solution was adjusted to a total volume of 100 ml with the same saline solution, dispensed in 1 ml portions into 1 ml capacity ampoule and then sterilized at 115 for 30 minutes to give liquid inhalant.

Example 163 Preparation of a pharmaceutical composition: powder inhalant Formulation:

Compound of the present invention ........... 200 /,tg Lactose ..................................... 4,000 /-Ig A 20 g portion of the compound of the present invention was uniformly mixed with 400 g of lactose, and a 200 mg portion of the mixture was packed in a powder inhaler for exclusive use to produce a powder inhalant.

Example 164 Preparation of a pharmaceutical composition: inhalation aerosol.
Formulation:

Compound of the present invention ............ 200 /-~g Dehydrated (Absolute) ethyl alcohol USP ...... 8,400 /~ig 1,1,1,2-Tetrafluoroethane (HFC-134A) ......... 46,810 /~g The active ingredient concentrate is prepared by dissolving 0.0480 g of the compound of the present invention in 2.0160 g of ethyl alcohol.
The concentrate is added to an appropriate filling apparatus. The active ingredient concentrate is dispensed into aerosol container, the headspace of the container is purged with Nitrogen or HFC-134A vapor (purging ingredients should not contain more than 1 ppm oxygen) and is sealed with valve. 11.2344 g of HFC-134A propellant is then pressure filled into the sealed container.

Claims (44)

1. A compound according to formula (I) wherein:
© is a phenyl ring, a heteroaromatic group having from 4 to 9 ring members and one or more heteroatoms selected from nitrogen, oxygen and sulphur atoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group;
- R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, a phenyl, a -OR4, -SR4, -NR4R5, -NHCOR4, -CONR4R5, -CN, -NO2, -COOR4 or -CF3 group, or a straight or branched C1 to C8 alkyl group which may optionally be substituted with a hydroxy group, wherein R4 and R5 each independently represent a hydrogen atom, straight or branched C1 to C8 alkyl group or together form a C3 to C10 alicyclic ring;
or R1 and R2 together form a C6 to C14 aromatic ring, a C3 to C10 alicyclic ring or a heterocyclic ring having from 3 to 10 ring members and one or more heteroatoms selected from nitrogen, oxygen and sulphur atoms;
- n is an integer from 0 to 4;
- A represents a -CH=CR6-, -CR6=CH-, -CR6R7-, -CO-, -O-, -S-, -S(O)-, SO2 or -NR6- group, wherein R6 and R7 each independently represent a hydrogen atom, straight or branched C1 to C8 alkyl group or R6 and R7 together form a C3 to C10 alicyclic ring;
- m is an integer from 0 to 8; provided that when in = 0, A is not -CH2-;
- p is an integer from 1 to 2 and the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons, B represents a group of formula I) or II):

wherein R10 represents a hydrogen atom, a hydroxy or methyl group; and R8 and R9 each independently represent wherein R11 represents a hydrogen atom, halogen atom, or a straight or branched C1 to C8 alkyl group and Q represents a single bond, -CH2-, -CH2-CH2, -O-, -O-CH2-, -S-, -S-CH2- or -CH=CH-; and X represents a pharmaceutically acceptable anion of a mono or polyvalent acid.
2. A compound according to claim 1, wherein any alkyl group present as R1 to R7 or R11 contains from 1 to 4 carbon atoms.
3. A compound according to claim 1 or 2 wherein p=2.
4. A compound according to any one of claims 1 to 3, wherein ©
represents a phenyl, pyrrolyl, thienyl, furyl, biphenyl, naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, imidazolyl or benzothiazolyl group.
5. A compound according to claim 4, wherein © represents a phenyl, pyrrolyl or thienyl group.
6. A compound according to any one of claims 1 to 5, wherein R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, hydroxy, methyl, tert-butyl, -CH2OH, 3-hydroxypropyl, -OMe, -NMe2, -NHCOMe, -CONH2, -CN, -NO2, -COOMe or -CF3 group.
7. A compound according to claim 6 wherein R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom or a hydroxy group.
8. A compound according to claim 7, wherein the halogen atom is fluorine.
9. A compound according to any one of claims 1 to 8, wherein A represents a -CH2-, -CH=CH-, -CO-, -NH-, -NMe-, -O- or -S- group; n is 0 or 1; and m is an integer from 1 to 6.
10. A compound according to claim 9, wherein A represents a-CH2-, -CH=CH- or -O- group and m is 1, 2 or 3.
11. A compound according to any one of claims 1 to 10, wherein the azoniabicyclo group is substituted on the nitrogen atom with a 3-phenoxypropyl, 2-phenoxyethyl, 3-phenylallyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 3-(2-hydroxyphenoxy)propyl, 3-(4-fluorophenoxy)propyl, 2-benzyloxyethyl, 3-pyrrol-1-ylpropyl, 2-thien-2-ylethyl or 3-thien-2-ylpropyl group.
12. A compound according to any one of claims 1 to 11, wherein B represents a group of formula (i) and R8 and R9 each independently represent a phenyl, 2-thienyl, 3-thienyl, 2-furyl, or 3-furyl group and R11 represents a hydrogen atom.
13. A compound according to any one of claims 1 to 11, wherein B represents a group of formula (ii) and Q represents a single bond; a -CH2-, -CH2-CH2- group or an oxygen atom.
14. A compound according to any one of claims 1 to 13, wherein X represents a bromide, chloride or trifluoroacetate anion.
15. A compound according to any one of claims 1 to 14, wherein the azoniabicyclo group is substituted in the 3-position.
16. A compound according to claim 15, wherein the substituent in the 3 position has (R) configuration.
17. A compound according to claim 16, wherein R8 is different from R9 in group (i), and the asymmetric carbon to which R8 and R9 are bonded has the (R) configuration.
18. A compound according to claim 16, wherein R8 is different from R9 in group (i), and the asymmetric carbon to which R8 and R9 are bonded has the (S) configuration.
19. A compound according to any one of claims 1 to 18, which is a single isomer.
20. A compound according to claim 1 which is 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane;
bromide 3(R)-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2 2]octane;
bromide 3(R)-(2,2-Diphenylpropionyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.
2.2]octane; bromide 3(R)-(2-Hydroxy-2-phenyl-2-thien-2-yl-acetoxy)-1-(3-phenoxypropyl)-1-azonia-bicyclo[2.2.2]octane; bromide 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-1-(3-phenylallyl)-1-azo niabicyclo[2.2.2]octane; bromide 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-1-(2-phenoxyethyl)-1-azo niabicyclo[2.2.2]octane; bromide 3(R)-(2-Furan-2-yl-2-hydroxy-2-phenylacetoxy)-1-(3-phenoxypropyl)-1-azo niabicyclo[2.2.2]octane; bromide 3(R)-(2,2-Dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo [2.2.2]octane; bromide 3(R)-(2-Hydroxy-2,2-di-thien-2-ylacetoxy)-1-phenethyl-1-azoniabicy clo[2.2.2]octane; bromide 3(R)-(2-Hydroxy-2,2-di-thien-2-ylacetoxy)-1-(4-phenylbutyl)-1-azonia bicyclo[2.2.2]octane; bromide 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azonia-bicyclo[2.2.2]octane; bromide 1-[3-(4-Fluorophenoxy)propyl]-3(R)-(2-hydroxy-2,2-dithien-2-ylaceto xy)-1-azoniabicyclo[2.2,2]octane; chloride 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(2-hydroxyphenoxy)pro pyl]-1-azoniabicyclo[2,2.2]octane; trifluoroacetate 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-pyrrol-1-ylpropyl)-1-azonia-bicyclo[2.2.2]oct ane; trifluoroacetate 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(2-thien-2-ylethyl)-1-azo niabicyclo[2.2.2]octane, bromide 3(R)-(2-Hydroxy-2,2-dithten-2-ylacetoxy)-1-(3-thien-2-ylpropyl)-1-a zoniabicyclo[2.2.2]octane; bromide 1-(2-Benzyloxyethyl)-3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-azoniabicyclo[2.2.2]
octane; trifluoroacetate 3(R)-(2-Hydroxy-2,2-dithien-3-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]
octane; bromide 1-(3-phenylallyl)-3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]
octane, bromide 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]
octane; bromide 3(R)-(9-Hydroxy-9[H]-fluorene-9-carbonyloxy)-1-phenethyl-1-azoniabicyclo[2.2.2]octane, bromide 3(R)-(9-Hydroxy-9H-fluorene-9-carbonyloxy)-1-(3-thien-2-ylpropyl)-1-azoniabicyclo[2.2.2]o ctane; bromide 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(3-phenylallyl)-1-azonia bicyclo[2.2.2]octane; bromide 3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(3-phenoxypropyl)-1-azo niabicyclo[2.2.2]octane; bromide 1-(4-Phenylbutyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane;
bromide 1-(2-Phenoxyethyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane;
bromide 1-(3-Phenoxypropyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane;
bromide 1-Phenethyl-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane;
bromide 3(R)-(9-Hydroxy-9[H]-xanthenes-9-carbonyloxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide 3(R)-(9-Hydroxy-9[H]-xanthene-9-carbonyloxy)-1-phenethyl-1-azoniabicy clo[2.2.2]octane, bromide 3(R)-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-1-(3-thien-2-ylpropyl)-1-azoniabicyclo[2.2.2]
octane; bromide or 3(R)-(9-Methyl-9[H]-xanthene-9-carbonyloxy)-1-(3-phenoxy-propyl)-1-azonia-bicyclo[2.2.2]
octane; bromide
21. A compound according to claim 1 which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; X-, wherein X-represents a pharmaceutically acceptable anion of a mono or polyvalent acid.
22. A compound according to claim 1, which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; bromide
23. A compound according to claim 1, which is 1-phenethyl-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2}; X-wherein X-represents a pharmaceutically acceptable anion of a mono or polyvalent acid.
24. A compound according to claim 1, which is 1-phenethyl-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]; octane;
bromide
25. A compound according to any one of claims 1 to 24, charactezised in that it has an IC50 value for muscarinic M3 receptors (Hm3) of less than 35 nM.
26. A process for the preparation of a compound of formula (I), as defined in any one of claims 1 to 24, which comprises reacting an alkylating agent of formula (II) with a compound of formula (III) wherein, in each of formulae I, II and III, R1, R2, R3, ©, A, X, B, n, m and p are as defined in any one of claims 1 to 24.
27. A process according to claim 26 characterised in that the resulting reaction mixture is purified by solid phase extraction
28. A compound of formula (III) wherein B and p are as defined in any one of claims 1, 3 and 12 and wherein the substituent on the azabicyclo group has (R)- configuration.
29. A compound according to claim 28 which is 9-Methyl-9[H]-fluorene-9-carboxylic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester;

9-Methyl-9[H]-xanthene-9-carboxylic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester;
or 2-Hydroxy-2,2-difuran-2-yl-acetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester.
30. A compound of formula (VII) wherein p and R8 are as defined in any one of claims 1, 5 or 12, and wherein the substituent on the azabicyclo group has (R) configuration.
31. A compound according to claim 30, wherein R8 is a 2-thienyl or 2-furyl group.
32. A compound according to claim 31 which is oxothien-2-yl-acetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester; or oxofuran-2-yl-acetic acid 1-azabicyclo[2,2.2]oct-3(R)-yl ester.
33. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 25 in admixture with a pharmaceutically acceptable carrier or diluent.
34. A compound according to any one of claims 1 to 25, for the treatment of a respiratory, urinary or gastrointestinal disease in a human or animal,
35. A pharmaceutical composition according to claim 33, for the treatment of a respiratory, urinary or gastrointestinal disease in a human or animal.
36. Use of a compound as defined in any one of claims 1 to 25, for the manufacture of a medicament for use in the treatment of respiratory, urinary or gastrointestinal disease.
37. Use of a pharmaceutical composition as defined in claim 33, for the manufacture of a medicament for use in the treatment of a respiratory, urinary or gastrointestinal disease.
38. Use of a compound as defined in any one of claims 1 to 25 for the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease, bronchial hyperreactivity, chronic bronchitis, asthma or rhinitis.
39. Use of a pharmaceutical composition as defined in claim 33, for the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease, chronic bronchitis, asthma or rhinitis.
40. Use of (a) a compound as defined in any one of claims 1 to 20 and (b) a .beta.-agonist, in the manufacture of a medicament for use in the treatment of a respiratory disease.
41. Use of (a) a compound as defined in any one of claims 1 to 20 and (b) a steroid, in the manufacture of a medicament for use in the treatment of a respiratory disease.
42. Use of (a) a compound as defined in any one of claims 1 to 20 and (b) an anti-allergic drug, in the manufacture of a medicament for use in the treatment of a respiratory disease.
43. Use of (a) a compound as defined in any one of claims 1 to 20 and (b) a phosphodiesterase IV inhibitor, in the manufacture of a medicament for use in the treatment of a respiratory disease.
44. Use according to any one of claims 40 to 43, wherein the medicament is for use in the treatment of chronic obstructive pulmonary disease, bronchial hyperreactivity, chronic bronchitis, asthma or rhinitis.
CA2381165A 1999-07-14 2000-07-07 Novel quinuclidine derivatives and medicinal compositions containing the same Expired - Lifetime CA2381165C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES009901580A ES2165768B1 (en) 1999-07-14 1999-07-14 NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ESP9901580 1999-07-14
PCT/EP2000/006469 WO2001004118A2 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands

Publications (3)

Publication Number Publication Date
CA2381165F CA2381165F (en) 2001-01-18
CA2381165A1 CA2381165A1 (en) 2001-01-18
CA2381165C true CA2381165C (en) 2009-10-27

Family

ID=8309225

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2381165A Expired - Lifetime CA2381165C (en) 1999-07-14 2000-07-07 Novel quinuclidine derivatives and medicinal compositions containing the same

Country Status (39)

Country Link
US (16) US6750226B2 (en)
EP (1) EP1200431B3 (en)
JP (2) JP4030040B2 (en)
KR (3) KR100854321B1 (en)
CN (2) CN1272334C (en)
AR (1) AR029760A1 (en)
AT (1) ATE235492T1 (en)
AU (1) AU2005202144B2 (en)
BE (1) BE2013C001I2 (en)
BG (1) BG65565B1 (en)
BR (1) BRPI0012434B8 (en)
CA (1) CA2381165C (en)
CO (1) CO5200759A1 (en)
CY (1) CY2013001I1 (en)
CZ (1) CZ304292B6 (en)
DE (2) DE60001840D1 (en)
DK (1) DK1200431T6 (en)
EE (1) EE04915B3 (en)
EG (1) EG24066A (en)
ES (2) ES2165768B1 (en)
FR (1) FR13C0001I2 (en)
HK (1) HK1042487B (en)
HU (1) HU228594B1 (en)
IL (1) IL147533A0 (en)
LU (1) LU92132I2 (en)
MY (1) MY126959A (en)
NO (2) NO329484B3 (en)
PE (1) PE20010397A1 (en)
PL (1) PL204024B1 (en)
PT (1) PT1200431E (en)
RU (2) RU2264401C3 (en)
SI (1) SI1200431T1 (en)
SK (1) SK287480B6 (en)
TR (1) TR200200768T2 (en)
TW (1) TWI284644B (en)
UA (1) UA73509C2 (en)
UY (2) UY26244A1 (en)
WO (1) WO2001004118A2 (en)
ZA (1) ZA200200232B (en)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
AR028948A1 (en) * 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
IL156499A0 (en) * 2000-12-22 2004-01-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
EP1353919B1 (en) * 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US7361787B2 (en) 2001-09-14 2008-04-22 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
IL162596A0 (en) * 2001-12-20 2005-11-20 S A L V A T Lab Sa 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
US7405224B2 (en) 2002-01-31 2008-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions
DE10203753A1 (en) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma New xanthene carboxylic acid esters, processes for their preparation and their use as medicines
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
ES2206021B1 (en) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRROLIDINIO.
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ES2203327B1 (en) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. NEW QUINUCLIDINE CARBAMATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2204295B1 (en) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF QUINUCLIDINE-AMIDE.
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1590345A1 (en) * 2002-12-23 2005-11-02 Ranbaxy Laboratories, Ltd. Xanthine derivatives as muscarinic receptor antagonists
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
AR044519A1 (en) 2003-05-02 2005-09-14 Novartis Ag DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
AR044134A1 (en) * 2003-05-02 2005-08-24 Novartis Ag DERIVATIVES OF QUINUCLIDINE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS.
CN100445281C (en) * 2003-05-02 2008-12-24 诺瓦提斯公司 Quinuclidine derivatives binding to mucarinic M3 receptors
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
JP2007524641A (en) 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド Substituted 4-amino-1-benzylpiperidine compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
AR045913A1 (en) * 2003-07-17 2005-11-16 Glaxo Group Ltd 8-AZABICICLO OLEFINIC DERIVATIVES [3,2,1] OCTANS AS ANTAGONISTS OF ACETILCOLINE MUSCARINIC RECEPTORS
TW200519109A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
AU2004262901B2 (en) * 2003-07-29 2010-05-13 Boehringer Ingelheim International Gmbh Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
JP2007500149A (en) * 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Drug comprising PDEIV inhibitor and anticholinergic agent for treating respiratory diseases
EP1651270B1 (en) * 2003-07-29 2007-03-21 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising betamimetics and an anticholinergic
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
MY143366A (en) 2003-10-14 2011-04-29 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
MXPA06004242A (en) * 2003-10-17 2006-06-28 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists field of the invention.
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
ES2239546B1 (en) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. NEW QUATERNIZED QUINUCLIDINE ESTERS.
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20060272A1 (en) 2004-05-24 2006-05-22 Glaxo Group Ltd (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
ES2317245T3 (en) * 2004-05-31 2009-04-16 Laboratorios Almirall, S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
DE602004018844D1 (en) * 2004-06-16 2009-02-12 Ranbaxy Lab Ltd XANTHINE DERIVATIVES SUITABLE AS ANTAGONISTS OF THE MUSCARIN RECEPTOR
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag ORGANIC COMPOUNDS.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
JP2008534611A (en) 2005-03-30 2008-08-28 シェーリング コーポレイション Drugs and methods combining anticholinergics, corticosteroids and long acting beta agonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP2009503101A (en) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド M3 muscarinic acetylcholine receptor antagonist
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
BRPI0614290A2 (en) * 2005-08-08 2011-03-22 Argenta Discovery Ltd bicyclo [2.2.1] hept-7-ylamine derivatives and their uses
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
AR058104A1 (en) 2005-10-21 2008-01-23 Novartis Ag ORGANIC COMPOUNDS
PE20071068A1 (en) 2005-12-20 2007-12-13 Glaxo Group Ltd 3- (4 - {[4- (4 - {[3- (3,3-DIMETHYL-1-PIPERIDINYL) PROPYL] OXY} PHENYL) -1-PIPERIDINYL] CARBONYL} -1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID, SALTS OF THE SAME, AS ANTAGONISTS OF THE H1 AND H3 RECEPTORS
CA2635649A1 (en) * 2006-01-06 2007-07-12 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and andolast
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MX2008013411A (en) 2006-04-20 2008-11-04 Glaxo Group Ltd Novel compounds.
JP5373599B2 (en) 2006-04-21 2013-12-18 ノバルティス アーゲー Purine derivatives for use as adenosine A2A receptor agonists
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
WO2008008021A1 (en) * 2006-07-14 2008-01-17 Astrazeneca Ab Inhalation system and delivery device for the administration of a drug in the form of dry powder.
JP2009543860A (en) 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ Novel tricyclic spiropiperidine compounds, their synthesis and their use as chemokine receptor activity modulators
ES2298049B1 (en) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. PROCEDURE FOR MANUFACTURING BROMIDE OF 3 (R) - (2-HIDROXI-2,2-DITIEN-2-ILACETOXI) -1- (3-PHENOXIPROPIL) -1-AZONIABICICLO (2.2.2) OCTANO.
JP2010504933A (en) 2006-09-29 2010-02-18 ノバルティス アーゲー Pyrazolopyrimidines as PI3K lipid kinase inhibitors
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0622827D0 (en) 2006-11-15 2006-12-27 Glaxo Group Ltd Sheet driver for use in a drug dispenser
JP2010513277A (en) * 2006-12-13 2010-04-30 ギリード・サイエンシズ・インコーポレーテッド Monophosphates as common prodrugs of muscarinic receptor antagonists and β-agonists for the treatment of COPD and chronic bronchitis
ATE493174T1 (en) 2007-01-10 2011-01-15 Irm Llc COMPOUNDS AND COMPOSITIONS AS CHANNEL-ACTIVATE PROTEASE INHIBITORS
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
MX2009008825A (en) * 2007-02-21 2009-10-12 Almirall Sa Novel methods.
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
KR20100005730A (en) 2007-05-07 2010-01-15 노파르티스 아게 Organic compounds
JP5656288B2 (en) 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Guazinin-containing compounds useful as muscarinic receptor antagonists
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
ES2602331T3 (en) 2007-12-10 2017-02-20 Novartis Ag Pyrazin-carboxamides of the amiloride type as ENaC blockers
US8017617B2 (en) * 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
MX2010012189A (en) 2008-05-13 2011-03-02 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists.
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
AU2009325091A1 (en) 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
CN102105448B (en) 2008-05-27 2013-11-13 阿斯利康(瑞典)有限公司 Phenoxypyridinylamide derivatives and use thereof in the treatment of PDE4 mediated disease states
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
MX2010013675A (en) 2008-06-10 2011-02-15 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers.
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
EP2391366B1 (en) 2009-01-29 2012-11-28 Novartis AG Substituted benzimidazoles for the treatment of astrocytomas
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
EA201171144A1 (en) 2009-03-19 2012-04-30 Мерк Шарп Энд Домэ Корп. MEDIATED RNA-INTERFERENCE INHIBITING THE EXPRESSION OF THE HOMEPHOLOGICAL GENE 1 BTB AND CNC, THE MAIN TRANSFCRIPTION FACTOR WITH LEUKIN LIGHTNING 1 (Bach1) USING SMALL INTERFACE
US20120004282A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp, RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521760A (en) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
PT2417106T (en) 2009-04-09 2017-02-13 Novartis Ag Process for preparing pyrrolidinium salts
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
UY32571A (en) 2009-04-24 2010-11-30 Glaxo Group Ltd COMPOUNDS DERIVED FROM PIRAZOL AMIDA
CA2759476C (en) 2009-04-30 2018-10-09 Julie Nicole Hamblin Novel compounds
PL2435025T3 (en) 2009-05-29 2017-08-31 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0910537D0 (en) 2009-06-18 2009-07-29 Ivax Pharmaceuticals Ireland Inhaler
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (en) 2009-08-12 2012-02-29 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
KR20120089463A (en) 2009-08-20 2012-08-10 노파르티스 아게 Heterocyclic oxime compounds
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
JP2013512878A (en) 2009-12-03 2013-04-18 グラクソ グループ リミテッド New compounds
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
ES2532213T3 (en) 2010-10-21 2015-03-25 Glaxo Group Limited Pyrazole compounds that act against allergic, immune and inflammatory conditions
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
JP2014505088A (en) 2011-02-10 2014-02-27 ノバルティス アーゲー [1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
CN103492384B (en) 2011-02-25 2016-05-11 诺华股份有限公司 As compound and the composition of TRK inhibitor
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
BR112014006223A8 (en) 2011-09-15 2018-01-09 Novartis Ag 6-substituted 3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines, their uses, pharmaceutical compositions, and combination
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP5886433B2 (en) 2011-09-16 2016-03-16 ノバルティス アーゲー Heterocyclic compounds for the treatment of cystic fibrosis
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
AU2012352153B2 (en) 2011-12-13 2018-07-26 Veracyte, Inc. Cancer diagnostics using non-coding transcripts
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
MX371119B (en) 2012-04-03 2020-01-17 Novartis Ag Combination products with tyrosine kinase inhibitors and their use.
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
CA2893663A1 (en) * 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Phenylethylpyridine derivatives as pde4-inhibitors
HRP20221034T1 (en) 2012-12-17 2022-11-11 Almirall S.A. Aclidinium for use in increasing physical activity in daily life in a patient suffering from chronic obstructive pulmonary disease
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
TR201902687T4 (en) 2013-03-15 2019-03-21 Pearl Therapeutics Inc Methods and systems for conditioning coarse crystalline materials.
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
CA2921621C (en) * 2013-07-13 2018-08-28 Beijing Fswelcome Technology Development Co., Ltd Quinine compounds, and optical isomers, preparation method and medical use thereof
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
JP6475707B2 (en) 2013-10-17 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ PI3K inhibitors for the treatment of respiratory diseases
CZ306791B6 (en) 2013-10-29 2017-07-12 Zentiva, K.S. An industrially applicable process of preparing aclidinium bromide of high purity
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
CN103755699A (en) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 Preparation method of 2-hydroyxl-2,2-dithienyl-2-polyglycolic acid-1-azabicyclo[2, 2, 2] octyl-3(R)-base ester
CN103755698A (en) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 Technology for preparing aclidinium bromide employing one-pot process
CZ2014188A3 (en) 2014-03-26 2015-10-07 Zentiva, K.S. Novel forms of aclidinium chloride and process for preparing thereof
JP6517319B2 (en) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ Substituted heteroaryl compounds and methods of use
MX2016013812A (en) 2014-04-24 2017-03-09 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors.
ES2667424T3 (en) 2014-04-24 2018-05-10 Novartis Ag Pyrazine derivatives as phosphatidyl-inositol-3-kinase inhibitors
KR20160145780A (en) 2014-04-24 2016-12-20 노파르티스 아게 Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
EA201692111A1 (en) 2014-05-12 2017-08-31 Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (en) 2014-07-31 2019-06-05 ノバルティス アーゲー Combination therapy
JP6693943B2 (en) * 2015-03-02 2020-05-13 株式会社Ｌｔｔバイオファーマ Quinuclidine derivative
PT108370B (en) 2015-03-30 2018-10-25 Hovione Farm S A ACLIDINE BROMETON PREPARATION PROCESS
WO2016162878A1 (en) * 2015-04-04 2016-10-13 Harman Finochem Limited An advantageous process for preparing 1-azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacetyl)oxy]-1-(3¬phenoxypropyl)-, bromide, (3r)- and its novel crystalline form-i
CZ2015257A3 (en) 2015-04-16 2016-10-26 Zentiva, K.S. Method of reducing particle size of [(3R)-1-(3-phenoxypropyl)chinuclidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetate bromide
CN105085355B (en) * 2015-06-25 2017-11-14 御盛隆堂药业有限责任公司 A kind of substituted pyrrolidine carboxylic acid's ester type compound and its preparation method and application
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
WO2018094392A1 (en) 2016-11-21 2018-05-24 Lupin Inc. Medicament dispenser
GB201700727D0 (en) 2017-01-16 2017-03-01 Teva Pharma Inhalers and airflow adaptors therefor
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190076607A1 (en) 2017-09-13 2019-03-14 Lupin Atlantis Holdings Sa Inhaler and mesh for an inhaler
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2019129801A1 (en) 2017-12-28 2019-07-04 Linnea S.A. Process for the purification of methyl-2,2-dithienylglycolate
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CA3146109A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (en) 2020-01-29 2021-11-01 瑞士商諾華公司 Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody
CN115916305A (en) 2020-03-25 2023-04-04 陆品公司 Multi-carrier medicament dispenser
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
MX2023000955A (en) 2020-07-23 2023-04-26 Lupin Inc Dose counter assemblies for medicament dispensers.

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (en) 1978-01-10 1979-08-03 Pharmindustrie NEW DERIVATIVES OF AZA-1 BICYCLO (2,2,2) OCTANE, USABLE AS MEDICINAL PRODUCTS
IT7920688V0 (en) 1979-02-05 1979-02-05 Chiesi Paolo Parma INHALER FOR PULVERULENT MEDICINAL SUBSTANCES, WITH COMBINED DOSER FUNCTION.
IT1116047B (en) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti DEVICE FOR THE QUICK INHALATION OF POWDER DRUGS BY PERSONS SUFFERING FROM ASTHMA
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
FR2539135B1 (en) 1983-01-11 1986-02-28 Essilor Int POLYURETHANE HYDROGELS AND MANUFACTURING METHOD
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
FI69963C (en) 1984-10-04 1986-09-12 Orion Yhtymae Oy DOSERINGSANORDNING
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
GB8718345D0 (en) * 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US4843074A (en) 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (en) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg INHALATOR
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (en) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
IT1237118B (en) 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (en) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg GAS-FREE INHALATION DEVICE
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
ES2161211T3 (en) 1990-09-06 2001-12-01 Pfizer ANTIMUSCARINIC BRONCODILATORS.
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
WO1992004928A2 (en) 1990-09-26 1992-04-02 Pharbita B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5263480A (en) 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (en) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg NEW ESTERS BI-AND TRICYCLIC AMINO ALCOHOLS, THEIR PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
GB9119705D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
DE4239402A1 (en) 1992-11-24 1994-05-26 Bayer Ag Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion
RO117414B1 (en) 1992-12-09 2002-03-29 Jager Paul D Waterbury Pharmaceutical composition of gas dispersoid in solution
NZ259241A (en) 1992-12-18 1996-12-20 Schering Corp Inhaler including a counter ring, a nozzle to break powder agglomerates and spring-biased, bi-directionally rotatable metering plate and powder house
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5569447A (en) * 1994-04-19 1996-10-29 The United States Of America Represented By The Secretary Department Of Health And Human Services Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives
EP0772655B1 (en) 1994-07-29 2000-03-01 Minnesota Mining And Manufacturing Company Acrylic syrup curable to a crosslinked viscoelastomeric material
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NO2005012I1 (en) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin and pharmaceutically acceptable salts thereof
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
SK284447B6 (en) 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Metered dose inhaler
ES2168488T3 (en) 1995-06-21 2002-06-16 Sofotec Gmbh & Co Kg PHARMACEUTICAL POWDER CARTRIDGE WITH INTEGRATED DOSING DEVICE AND INHALER FOR POWDERED MEDICINES.
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (en) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg New drugs and their use
DE19536902A1 (en) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Miniature fluid pressure generating device
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
SE9603669D0 (en) 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (en) * 1996-12-05 2000-04-28 Astra Ab NEW BUDESONIDE FORMULATION
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
IL140353A0 (en) 1998-06-18 2002-02-10 Boehringer Ingelheim Pharma Pharmaceutical formulations for aerosols with two or more active substances
ITMI981671A1 (en) 1998-07-21 2000-01-21 Zambon Spa PHTHALAZINIC DERIVATIVES INHIBITORS OF PHOSPHODISTERASE 4
PT1102579E (en) 1998-08-04 2003-07-31 Jago Res Ag MEDICINAL AEROSOL FORMULATIONS
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19847968A1 (en) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit.
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (en) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ES2165768B1 (en) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
SE9902935D0 (en) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (en) 1999-12-29 2004-03-19 Valeo Climatisation MULTI-CHANNEL TUBE HEAT EXCHANGER, PARTICULARLY FOR MOTOR VEHICLES
WO2001054728A1 (en) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
EA005028B1 (en) 2000-01-31 2004-10-28 Пфайзер Продактс Инк. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0008485D0 (en) 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
US6777132B2 (en) 2000-04-27 2004-08-17 Valence Technology, Inc. Alkali/transition metal halo—and hydroxy-phosphates and related electrode active materials
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
JP5392880B2 (en) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Stable pharmaceutical solution formulation for pressurized metered dose inhalers
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (en) 2000-07-27 2003-07-23 Smithkline Beecham Corp METHOD FOR REDUCING ASSOCIATED EXCERBATIONS COPD AMBITO
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6852728B2 (en) 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10062712A1 (en) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and corticosteroids
DE10110772A1 (en) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and PDE-IV inhibitors
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6608054B2 (en) 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US6620438B2 (en) 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020122773A1 (en) 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20020151541A1 (en) 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
JP2004512359A (en) 2000-10-31 2004-04-22 ベーリンガー　インゲルハイム　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　ウント　コンパニー　コマンディトゲゼルシャフト Novel pharmaceutical compositions based on anticholinergics and corticosteroids
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (en) 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
IL156499A0 (en) 2000-12-22 2004-01-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
EP1353919B1 (en) 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
US20020189610A1 (en) 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
DE10104367A1 (en) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions containing betamimetics with fewer side effects
DE10104370A1 (en) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions with fewer side effects
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
ATE347361T1 (en) 2001-05-25 2006-12-15 Boehringer Ingelheim Pharma COMBINATION OF A PDE4 INHIBITOR WITH TIOTROPIUM FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES
NZ529335A (en) 2001-05-25 2005-09-30 Pfizer A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10129703A1 (en) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Atomizing system for a powder mixture and method for dry powder inhalers
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (en) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US6919325B2 (en) 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
EP1429768B1 (en) 2001-09-14 2016-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Novel medicaments for inhalation
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
DE10202940A1 (en) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Cartridge for a powder inhaler
US6790856B2 (en) 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
EP3536344B1 (en) 2002-03-01 2020-02-19 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
DE10216429A1 (en) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Synergistic medicaments for treating inflammatory or obstructive respiratory tract diseases, containing quaternized scopine ester anticholinergic agent and steroid, e.g. budesonide
US7094788B2 (en) 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
DE10216333A1 (en) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma New diarylacetic acid quaternized azabicycloheptyl esters, are anticholinergic agents useful e.g. for treating asthma, chronic obstructive pulmonary disease, arrhythmia or menstrual disorders
ES2206021B1 (en) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRROLIDINIO.
ES2195785B1 (en) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
BR0310084A (en) 2002-05-17 2005-02-15 Novartis Ag A pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic.
ES2204295B1 (en) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF QUINUCLIDINE-AMIDE.
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
ES2211315B1 (en) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. NEW TRICYCLE COMPOUNDS.
CA2506949A1 (en) 2002-11-27 2004-06-10 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (en) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
DE10307759B3 (en) 2003-02-19 2004-11-18 Schering Ag Trimers of macrocyclically substituted benzene derivatives, their production and use as contrast media and pharmaceutical compositions containing them
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
DE602004011494T2 (en) 2003-03-28 2009-01-22 Nycomed Gmbh SYNERGISTIC COMBINATION CONTAINS ROFLUMILAST AND AN ANTICHOLINERGIC AGENT SELECTED FROM TIOTROPIUM SALTS FOR THE TREATMENT OF RESPIRATORY DISEASES
US20060189642A1 (en) 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20050026886A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026887A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
EP1651270B1 (en) 2003-07-29 2007-03-21 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising betamimetics and an anticholinergic
AU2004262901B2 (en) 2003-07-29 2010-05-13 Boehringer Ingelheim International Gmbh Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
JP2007500149A (en) 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Drug comprising PDEIV inhibitor and anticholinergic agent for treating respiratory diseases
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
CA2534120C (en) 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
US20050025718A1 (en) 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10347994A1 (en) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Aqueous aerosol preparation
ES2232306B1 (en) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
JP4700014B2 (en) 2004-02-06 2011-06-15 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト Combination of anticholinergic agent and type 4 phosphodiesterase for the treatment of respiratory diseases
SI1713473T1 (en) 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
CN1905902A (en) 2004-02-06 2007-01-31 Meda制药有限及两合公司 Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases
US7712077B2 (en) * 2004-02-27 2010-05-04 International Business Machines Corporation Method and system for instantiating components conforming to the “COM” specification in custom contexts
ES2239546B1 (en) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. NEW QUATERNIZED QUINUCLIDINE ESTERS.
DE102004016179A1 (en) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Compounds for the treatment of proliferative processes
ES2317245T3 (en) 2004-05-31 2009-04-16 Laboratorios Almirall, S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
ES2257152B1 (en) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
JP2008534611A (en) 2005-03-30 2008-08-28 シェーリング コーポレイション Drugs and methods combining anticholinergics, corticosteroids and long acting beta agonists
ES2298049B1 (en) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. PROCEDURE FOR MANUFACTURING BROMIDE OF 3 (R) - (2-HIDROXI-2,2-DITIEN-2-ILACETOXI) -1- (3-PHENOXIPROPIL) -1-AZONIABICICLO (2.2.2) OCTANO.
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
US20100063016A1 (en) 2007-02-19 2010-03-11 Cipla Limited Pharmaceutical Combinations
MX2009008825A (en) 2007-02-21 2009-10-12 Almirall Sa Novel methods.
WO2009004502A1 (en) 2007-07-03 2009-01-08 Nxp B.V. Calibration of an amr sensor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
HRP20221034T1 (en) 2012-12-17 2022-11-11 Almirall S.A. Aclidinium for use in increasing physical activity in daily life in a patient suffering from chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
US20060106056A1 (en) 2006-05-18
AR029760A1 (en) 2003-07-16
DK1200431T6 (en) 2015-09-28
KR20020021155A (en) 2002-03-18
BE2013C001I2 (en) 2019-05-21
EP1200431A2 (en) 2002-05-02
US20070099953A1 (en) 2007-05-03
CN1824664A (en) 2006-08-30
RU2005121162A (en) 2007-01-20
CN1373760A (en) 2002-10-09
US20080221155A1 (en) 2008-09-11
NO2013002I2 (en) 2013-09-09
US20130310353A1 (en) 2013-11-21
PL204024B1 (en) 2009-12-31
ES2165768B1 (en) 2003-04-01
AU6433000A (en) 2001-01-30
US20190183867A1 (en) 2019-06-20
AU2005202144A1 (en) 2005-06-09
ES2193098T3 (en) 2003-11-01
HUP0202100A2 (en) 2002-10-28
SK287480B6 (en) 2010-11-08
US9056100B2 (en) 2015-06-16
EP1200431B1 (en) 2003-03-26
HUP0202100A3 (en) 2003-09-29
US7897617B2 (en) 2011-03-01
US20100234333A1 (en) 2010-09-16
EE04915B1 (en) 2007-10-15
US7109210B2 (en) 2006-09-19
EG24066A (en) 2008-05-08
EE04915B3 (en) 2016-07-15
US10588895B2 (en) 2020-03-17
KR100773844B1 (en) 2007-11-06
CZ2002121A3 (en) 2002-11-13
CZ304292B6 (en) 2014-02-19
CO5200759A1 (en) 2002-09-27
FR13C0001I2 (en) 2013-11-01
US8513279B2 (en) 2013-08-20
NO20020180L (en) 2002-03-13
NO2013002I1 (en) 2013-02-11
AU779881B2 (en) 2005-02-17
US10034867B2 (en) 2018-07-31
JP2005350476A (en) 2005-12-22
US20050209272A1 (en) 2005-09-22
SK432002A3 (en) 2003-04-01
PT1200431E (en) 2003-07-31
US8802699B2 (en) 2014-08-12
DE60001840T2 (en) 2003-12-11
USRE46417E1 (en) 2017-05-30
US20170319557A1 (en) 2017-11-09
CA2381165F (en) 2001-01-18
JP2003504368A (en) 2003-02-04
JP4951217B2 (en) 2012-06-13
US20120122826A1 (en) 2012-05-17
US7358260B2 (en) 2008-04-15
KR100854321B1 (en) 2008-08-26
US20150246026A1 (en) 2015-09-03
RU2306312C2 (en) 2007-09-20
CN1272334C (en) 2006-08-30
SI1200431T1 (en) 2003-10-31
CY2013001I2 (en) 2015-10-07
BG65565B1 (en) 2008-12-30
CA2381165A1 (en) 2001-01-18
KR20070009744A (en) 2007-01-18
UY26244A1 (en) 2000-12-29
DK1200431T3 (en) 2003-07-21
KR100854315B1 (en) 2008-08-26
BRPI0012434B8 (en) 2021-05-25
US20110118223A1 (en) 2011-05-19
US20160296503A1 (en) 2016-10-13
BRPI0012434B1 (en) 2016-03-22
US7078412B2 (en) 2006-07-18
US9687478B2 (en) 2017-06-27
US20140303126A1 (en) 2014-10-09
BR0012434A (en) 2002-04-02
US7750023B2 (en) 2010-07-06
IL147533A0 (en) 2002-08-14
WO2001004118A2 (en) 2001-01-18
ZA200200232B (en) 2003-04-10
RU2264401C2 (en) 2005-11-20
JP4030040B2 (en) 2008-01-09
US8129405B2 (en) 2012-03-06
DK1200431T5 (en) 2005-01-31
NO20020180D0 (en) 2002-01-14
WO2001004118A3 (en) 2001-07-19
NO329484B3 (en) 2013-04-29
UY33494A (en) 2013-04-05
ES2165768A1 (en) 2002-03-16
DE60001840T3 (en) 2015-10-08
HU228594B1 (en) 2013-04-29
HK1042487B (en) 2003-07-18
CN100451018C (en) 2009-01-14
TR200200768T2 (en) 2002-07-22
US6750226B2 (en) 2004-06-15
ES2193098T7 (en) 2012-12-13
LU92132I2 (en) 2013-03-18
DE60001840D1 (en) 2003-04-30
RU2264401C3 (en) 2018-06-01
EE200200017A (en) 2003-04-15
UA73509C2 (en) 2005-08-15
US20030055080A1 (en) 2003-03-20
FR13C0001I1 (en) 2013-01-03
US7196098B2 (en) 2007-03-27
US20040132768A1 (en) 2004-07-08
CY2013001I1 (en) 2015-10-07
NO329484B1 (en) 2010-10-25
PL357160A1 (en) 2004-07-12
EP1200431B3 (en) 2015-06-24
KR20070007396A (en) 2007-01-15
US9333195B2 (en) 2016-05-10
MY126959A (en) 2006-11-30
PE20010397A1 (en) 2001-04-11
AU2005202144B2 (en) 2007-06-14
DE60001840T4 (en) 2015-11-26
BG106301A (en) 2002-08-30
TWI284644B (en) 2007-08-01
ATE235492T1 (en) 2003-04-15

Similar Documents

Publication Publication Date Title
US10588895B2 (en) Quinuclidine derivatives and medicinal compositions containing the same
US20060106055A1 (en) Novel quinuclidine derivatives and medicinal compositions containing the same

Legal Events

Date Code Title Description
EEER Examination request
NARC Re-examination certificate

Effective date: 20180417

MKEX Expiry

Effective date: 20200707